Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids

ABSTRACT

The invention provides miniaturized lateral flow chromatographic and lateral flow chromatographic microarray devices (LFM). The miniaturization of lateral flow nucleic acid detection achieved by the present invention offers reduced reagent use, femtomole sensitivity, excellent linear dynamic range, and rapid detection. Moreover, the small feature sizes of capture oligonucleotides renders the potential information capacity of the platform comparable to more traditional spotted fluorescence microarrays as well as improving sensitivity. The LFM devices exemplified herein enable analytes to be detected within 10 seconds from the time of sample introduction to the LFM device. Sample volumes may be as low as about 10 microliters, significantly reducing assay costs and ameliorating reagent storage logistics. Additionally, the miniaturization of lateral flow opens the door to highly multiplexed assays, allowing many proteins or nucleic acids to be detected in a single assay.

RELATED APPLICATIONS

This patent application claims the benefit of the filing date of U.S.Provisional patent application No. 60/839,537 filed Aug. 22, 2006 andProvisional patent application No. 60/925,210 filed Apr. 18, 2007 under35 U.S.C. 119(e).

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSOREDRESEARCH OR DEVELOPMENT

This invention was made with government support under Contract No.DE-AC52-06NA25396, awarded by the United States Department of Energy.The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

The threat presented by biological weapons, global heath care issues andemerging diseases of natural origin lend urgency to the development ofrapid, field-deployable pathogen detection and diagnostic tools (1,2).Ideally, to be of general field utility, a diagnostic device must becapable of sensitive and specific pathogen detection while retainingsimplicity of use and independence from complex laboratoryinstrumentation (3). Additional challenges are presented by the need toscreen samples for multiple pathogenic or toxic agents, a characteristichighly desirable in cases where commonalities in early symptompresentation confound differential diagnoses.

While nucleic acid-based assays for pathogen detection andidentification offer sensitivity, specificity and resolution, they arerelatively elaborate and often costly, limiting their utility forpoint-of-care diagnostics and deployment under field conditions where asupporting laboratory infrastructure is limited or absent. Reliance uponpolymerase chain reaction (PCR) and fluorescent detection of amplifiednucleic acids has contributed significantly to the complexity and costof nucleic acid diagnostics (2,4-6). Retaining assay sensitivity, whilecircumventing requirements for thermocyclers and fluorescence detectionhardware, remains a significant challenge.

The recent advent of DNA microarray technology has promised to increasethe information capacity of nucleic acid diagnostics and enable thehighly multiplexed detection of genetic signatures (7). The potential ofDNA microarrays to detect, in parallel, large panels of distinct nucleicacid sequences has proven to be a powerful technique for many laboratoryapplications (for review see (8)). Nonetheless, the reliance of thistechnology on costly instrumentation for high-resolution fluorescencesignal transduction severely limits the utility of microarrays for fieldapplications where a laboratory infrastructure is limited orunavailable. Additionally, the long hybridization incubations requiredfor microarray assays increase sample-to-answer times beyond what wouldbe acceptable for a rapid screening assay. Though microarrayhybridization times as short as 500 seconds have been reported (9), suchmethods employ relatively elaborate microfluidic designs that remainreliant upon fluorescent detection and do not address the need for lowcost, easily manufactured devices that can be used without costlysupporting instrumentation.

In contrast to DNA-based assays, immunoassays have found widespreadacceptance in low cost, easily used formats, perhaps the most notable ofwhich is the chromatographic lateral flow immunoassay (for a review see(10)). Lateral flow assays, also known as hand-held assays or dipstickassays, are used for a broad range of applications where rapid antigendetection is required in an easily used, low cost format. Expanding thedomain of lateral flow chromatography to nucleic acid detection, anumber of recent reports have described lateral flow detection of PCRproducts using a variety of capture and detection schemes (11-14).Unfortunately, the utility of lateral flow detection in the context of aPCR-based assay is severely limited by the fact that reliance onthermocycling hardware largely negates the potential benefit of theotherwise highly simplified lateral flow platform. Additionally, aPCR-based approach to lateral flow detection necessitates each PCRreaction be subjected to post-amplification manipulations required togenerate single-stranded products for hybridization-based detection.

Recent work has sought to alleviate reliance on PCR through employingisothermal nucleic acid amplification schemes or direct detection ofunamplified genetic material. Enabled by the use of up-convertingphosphor reporters, unamplified Streptococcus pneumoniae DNA sequencehas been detected using a lateral flow assay format (15). Up-convertingphosphor technology, while sensitive, remains dependent upon thehardware required to detect phosphor emission (16). The use of simplecalorimetric detection schemes that circumvent the requirements forcomplex instrumentation require an upstream amplification strategy toattain suitable sensitivity. Isothermal nucleic acid amplificationcoupled with lateral flow detection has been reported for assays makinguse of cycling probe technology (CPT, (17)) and nucleic acidsequence-based amplification (NASBA, (18-20)) (21-25). While the work byFong et al (21) made use of a lateral flow immuno-assay for DNAdetection, the RNA targets amplified by NASBA in the work fromBaeumner's group (22-25) were detected using a lateral flow systemenabled by the use of liposome encapsulated dye and a sandwichhybridization assay similar to that reported by Rule et al (12). Whileshown to display nanomolar sensitivity, the reported dye encapsulatingliposome-based methods require additional washing steps and theliposomes are relatively labile, must be custom synthesized, and storedunder stabilizing hydrated conditions (26).

SUMMARY OF THE INVENTION

The invention provides miniaturized lateral flow chromatographic andlateral flow chromatographic microarray devices (collectively, “LFMdevices”), also termed “DNA dipstick”, “nucleic acid dipstick”, LFMdipstick” and “dipsick” devices, as well as diagnostic assay methodsutilizing LFM technology and dipsticks and related diagnostic kitscomprising LFM dipsticks.

The LFM technology and LFM devices of the invention offer many of theadvantages of microarray technology yet retain the simplicity of lateralflow-based platforms. The miniaturization of lateral flow nucleic aciddetection achieved by the present invention offers reduced reagent use,femtomole sensitivity, excellent linear dynamic range, and rapiddetection. Moreover, the small feature sizes of capture oligonucleotidesrenders the potential information capacity of the platform comparable tomore traditional spotted fluorescence microarrays as well as improvingsensitivity. The LFM devices exemplified herein enable analytes to bedetected within 10 seconds from the time of sample introduction to theLFM device. Sample volumes may be as low as about 10 microliters,significantly reducing assay costs and ameliorating reagent storagelogistics. Additionally, the miniaturization of lateral flow opens thedoor to highly multiplexed assays, allowing many proteins or nucleicacids to be detected in a single assay.

Coupled with an isothermal amplification technique, LFM provides afacile means of rapidly detecting nucleic acid targets whilecircumventing hardware requirements for fluorescence detection and PCRthermocycling.

The power of LFM is demonstrated in the Examples, infra. Morespecifically, Example 8 illustrates the utility of the lateral flowmicroarray (LFM) approach for sensitive detection and discrimination ofclosely related microbial signatures when present as minority sequencesin complex nucleic acid mixtures, using an assay based on the nonsensemutation in the plcR gene of B. anthracis, that is absent in the nearphylogenetic neighbors B. thuringiensis and B. cereus (27,28). Theresults demonstrate that LFMs, making use of stable detection reagentssuitable for dry storage, can be used to detect as little as 250 amolanalyte within 2 minutes of sample addition. The miniaturization oflateral flow detection decreases reagent consumption andsample-to-answer times while increasing the potential informationcapacity of the platform to enable the development of highly multiplexednucleic acid detection assays.

In one aspect, the invention provides a lateral flow chromatographicdevice for detecting the presence of at least one single-stranded targetnucleic acid analyte in a fluid sample, comprising a chromatographictest strip which comprises (a) a sample receiving zone for receiving analiquot of the sample and for receiving a labeled detectionoligonucleotide, which detection oligonucleotide comprises a sequencewhich is complementary to a first sequence of the target nucleic acid;and, (b) a capture zone in lateral flow contact with the samplereceiving zone, said capture zone comprising a microporous membrane,onto which at least one capture oligonucleotide is immobilized at afeature size of 500 μm diameter or smaller, and which comprises asequence which is complementary to a second sequence of the targetnucleic acid. In some embodiments, the microporous membrane is 3 mm orless in width. The lateral flow chromatographic device may combine thesample receiving zone and the capture zone, such that they comprise acontiguous microporous membrane. The microporous membrane is a lateralflow compatible nitrocellulose membrane having a pore size of between0.2 and 20 μm. The detection oligonucleotide is labeled with adetectable particle of between 0.02 and 1 μm in diameter, includingwithout limitation, polystyrene microspheres, latex particles, nano-goldparticles, colloidal gold particles, metal particles, magneticparticles, fluorescently detectable particles, and semi-conductornanocrystals. In some embodiments, the detection oligonucleotidecomprises a first portion having a sequence complementary to a part ofthe target sequence and a second portion having a non-target specificsequence of at least 9 nucleotides, which second portion is adjacent tothe label. The second portion may, for example, be a poly (A) or poly(T) sequence of at least 9 nucleotides.

In some embodiments, the first sequence and second sequence of thetarget nucleic acid are adjacent within 2 bases, in order to takeadvantage of “base stacking” hybridization stability.

In another aspect, the invention provides a lateral flow chromatographicdevice for detecting the presence of at least one single-stranded targetnucleic acid analyte in a fluid sample, comprising a lateral flow matrixwhich defines a flow path and which comprises in series: (a) a samplereceiving zone for receiving an aliquot of a fluid sample; (b) alabeling zone in lateral flow contact with said sample receiving zone,wherein the labeling zone comprises a porous material containing atleast one detection oligonucleotide reversibly bound thereto, whichdetection oligonucleotide is complementary to a first sequence of thetarget nucleic acid and is coupled to a detectable label; and, (c) acapture zone in lateral flow contact with said labeling zone, saidcapture zone comprising a microporous membrane, onto which at least onecapture oligonucleotide is immobilized at a feature size of 500 μmdiameter or smaller. In some embodiments, the microporous membrane is 3mm or less in width. The lateral flow chromatographic device may combinethe sample receiving zone and the capture zone, such that they comprisea contiguous microporous membrane. The microporous membrane is a lateralflow compatible nitrocellulose membrane having a pore size of between0.2 and 20 μm. The detection oligonucleotide is labeled with adetectable particle of between 0.02 and 1 μm in diameter, includingwithout limitation, polystyrene, microspheres, latex particles,nano-gold particles, colloidal gold particles, metal particles, magneticparticles, fluorescently detectable particles, and semi-conductornanocrystals. In some embodiments, the detection oligonucleotidecomprises a first portion having a sequence complementary to a part ofthe target sequence and a second portion having a non-target specificsequence of at least 9 nucleotides, which second portion is adjacent tothe label. The second portion may, for example, be a poly (A) or poly(T) sequence of at least 9 nucleotides.

In some embodiments, the first sequence and second sequence of thetarget nucleic acid are adjacent within 2 bases, in order to takeadvantage of “base stacking” hybridization stability.

In another aspect, the invention provides an assay method of testing forthe presence of a target nucleic acid in a liquid sample, comprisingapplying or contacting the liquid sample to the sample receiving zone ofthe lateral flow chromatographic device of the invention, allowing thesample to transport by capillary action through the capture zone, anddetecting the presence or absence of the target nucleic acid bydetecting the presence of the label at the relevant capture zonefeature.

In another aspect, the invention provides a method for detecting thepresence of a target nucleic acid in a biological sample, comprising:(a) providing a biological sample suspected of containing the targetnucleic acid sequence; (b) releasing nucleic acid from the biologicalsample; (c) amplifying the target nucleic acid using nucleic acidsequence based amplification (NASBA) to generate a solution containingamplified single-stranded RNA complementary to the target nucleic acid,if present in the extracted DNA and/or RNA from the biological sample;and, (d) assaying for the presence of the complementary RNA targetnucleic acid using the assay method above.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Detection of DNA hybridization over range of captureoligonucleotide deposition concentrations on DNA dipstick. See Example1.

FIG. 2. See Example 2. (A) Dipstick exposed to 100 μl of samplecontaining 5 nM cya target sequence (i.e. 500 fmol target sequence)(5′-AAGCTTCAGGTTTAGTACCAGMCATGCAGATGCTTTTAA-3′) [SEQ ID NO: 1]. Signalis detectable as a blue dot only at the cya capture feature. (B)Dipstick exposed to 100 μl of sample containing 5 nM capB targetsequence (5′-TTATCTGGGMGACCATGTAATCAAATTTTCGTAAGAATTC-3′) [SEQ ID NO:2]. Specific signal is generated at the cognate capB capture feature ofthe dipstick. (C) Dipstick exposed to 100 μl of sample containing 5 nMpagA target sequence (5′-TTCGAATTACTAAATCCTGCAGATACACTCCCACCAATAT-3′)[SEQ ID NO: 3]. Signal is detected only at the pagA capture site. Inthis particular dipstick, the negative results at the cya and capBcapture sites can be visualized as faint white areas of microsphereexclusion at their respective capture positions. (D) Triplex dipstickdetection of all three target sequences each present at a concentrationof 5 nM in a 100 μl sample volume. For all panels, signal was visuallydiscernible within 10 minutes.

FIG. 3. Sensitivity and detection times for DNA dipstick and DNAdipstick microarrays. See Example 3.

FIG. 4. Sensitivity and detection times for DNA dipstick microarrays,see Example 3.

FIG. 5. (A) NASBA primer binding sites are shown in the relevant regionof the predicted B. anthracis plcR mRNA sequence based on GenBankaccession number AY265698 [SEQ ID NO: 4]. The terminal 3′ base of plc-P1is complementary to the U of the ochre stop codon, indicated with anarrowhead, diagnostic for B. anthracis. (B) The predicted nucleotidesequence plcR mRNA in the region represented by synthetic target dnaR89[SEQ ID NO: 5]. The binding sites of detection probe R-57-76-3TN, aswell as capture probes R-77-96, R36-55 and R-24-43 are indicated.

FIG. 6. (A) A compact plastic housing was designed to a carry conjugaterelease pad and a LFM membrane. A small port is used to introduce the 10μl sample volume and a rectangular window allows direct visualization ofthe microarray capture features. The device is 39×5 mm. (B) A schematicrepresentation of the hybridization sandwich assay used for LFM-basednucleic acid detection. Carboxyl-polystyrene dyed microspheres arelinked to amine modified detection oligonucleotide R-57-76-3TN. Themicrosphere/analyte complex forms by hybridization as sample solutionliberates dried microspheres from the conjugate release pad. Thiscomplex is captured from solution by hybridization to immobilizedcapture probes as capillary flow transports the sample/bead solutionthrough the large pore nitrocellulose matrix. The resulting increase inlocal microsphere concentration, at capture features complementary tothe target analyte, rapidly produces a colorimetric signal visible tothe naked eye and easily detected at low concentrations using widelyavailable flatbed scanners. The hybridization based nature of the assayrender it well suited for multiplexed detection.

FIG. 7. (A) LFM substrates patterned with different concentrations ofcapture oligonucleotides R-77-96, R-36-55, and R-24-43 were used todetect dnaR89 with R-57-76-3TN microspheres. Signals generated atmicroarray capture features printed at 200, 400 and 800 μM werequantified following lateral flow of samples containing 5, and 20 fmoldnaR89. Signals were normalized for each capture probe and targetconcentration. Average signal intensities were calculated and presentedin this bar graph. 400 μM printing concentrations consistently providedthe strongest signal independent of capture sequence or dnaR89concentration. (B) Scatter plot of normalized signal intensity versusSSC concentration. LFM running buffer was optimized for SSCconcentration using R-57-76-3TN to detect dnaR89 (circles) or plcRivt(squares). (C) Line plot of normalized signal intensity versus formamideconcentration. Formamide concentrations between 0 and 20% in LFM runningbuffer based on 4×SSC were evaluated for dnaR89 (circles) and plcRivt(squares). 5% formamide provided near optimal detection of both dnaR89and plcRivt. (D) Line plot of normalized signal intensity versus theR-57-76-3TN to microsphere ratio. 2.2×10⁴ oligonucleotides/bead incoupling reactions provided the best performing conjugated microspherepopulations as judged by hybridization sandwich assay signal intensity.

FIG. 8. Representative LFMs are shown following detection of theindicated amounts of dnaR89. The microarray physical layout is providedin the color legend. The panel labeled “Ponceau S” is an LFM prior tosample addition. Ponceau S allows visualization of successfuloligonucleotide deposition but migrates away from the capture zoneduring sample transport across the substrate. Contrast was adjustedusing the Auto Contrast function in Photoshop CS2 to increasereproduction contrast. Auto Contrast adjustment was not used for imagessubjected to quantification. The bar is 600 μm for all LFM panels.

FIG. 9. (A) The relative performance of three different captureoligonucleotides (R-77-96, circle/solid line; R-36-55, square/solidline; R-24-43, diamond/dashed line) was determined using varying amountsof dnaR89 from 0 to 200 fmol. The capture probe R-77-96 providessignificantly more sensitive detection than the other capture sequencesevaluated using R-57-76-3TN coupled microspheres. (B) R-77-96 signalintensity versus amol dnaR89 from 0 to 2500 amol is plotted with alinear regression line (R²=0.989). (C) R-24-43 signal intensity versusfmol dnaR89 from 2.5 fmol to 100 fmol plotted with a linear regressionline (R²=0.968). For all parts error bars are the 95% confidenceinterval (one tailed, n=6).

FIG. 10. Time course of LFM detection: 10 μl samples containing either1000 fmol (circle), 100 fmol (square) or 10 fmol (diamond) dnaR89 wererun on appropriately patterned LFMs. Video data were collected andcolorimetric signal intensity measured from video frames at R-77-96capture features. Capillary transport of the 10 μl sample was completeby 120 seconds. Lines represent logarithmic curve fits to the data.

FIG. 11. (A) Indicated amounts of total cellular RNA from B. anthracisSterne strain 7702 or, as a negative control, 2 ng B. thuringiensisstrain HD 621 RNA (0 fg) were introduced to 1 μg of total human cellularRNA isolated from HeLa S3 cells. RNA mixtures were subjected to NASBAamplification for 60 min after which 2 μl aliquots of the NASBAreactions were mixed with 8 μl of LFM running buffer and introduced toLFMs. Enlarged LFM sub-regions are shown following Auto Contrastadjustment in Photoshop. The legend indicates microarray elementidentities: (+) dnaR89 as a positive hybridization control, (−)R-57-76as negative hybridization control, (24-43) capture probe R-24-43,(36-55) capture probe R-36-55, (77-96) capture probe R-77-96. (B) Graphof quantified signals from B. anthracis and B. thuringiensis challengedLFMs with linear regression line (R²=0.970). 0 fg B. anthracis totalcellular RNA data point contains 2 ng B. thuringiensis total cellularRNA in addition to 1 μg human total cellular RNA. Error bars depictmeasurement standard deviation (three determinations).

FIG. 12. Dual reporter LFM. Snapshots of a single LFM visualized underambient lighting (A) revealing dyed microsphere colorimetric signal andunder UV-LED flashlight illumination (B) revealing signal generated byfluorescent semi-conductor nanocrystals (biotin conjugated QuantumDots). The LFM membrane was challenged with dnaR89 detected usingbiotinylated detection oligonucleotide R-57-76-3TBIO. The detectionoligonucleotide sequence is: 5′-AGGTGAGACATAATCATGCATTTTTTTTTU-biotinTTTTU-biotinTTTTU-biotin3′ [SEQ ID NO: 6].

FIG. 13. Linearity of semi-conductor nanocrystal-based LFM detection.Varying quantities of dnaR89 were detected by LFM using R-57-76-3TBIOand streptavidin conjugated semi-conductor nanocrystals. The resultingLFMs were quantified on an Axon GenePix 4200 Pro microarray scannerusing GenePix Pro 6.0 software. Background corrected mean signal valuesare shown plotted versus fmols of dnaR⁸⁹. The assay exhibits excellentlinearity (R²=0.991) over a 1000-fold range of target.

DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise defined, all terms of art, notations and otherscientific terminology used herein are intended to have the meaningscommonly understood by those of skill in the art to which this inventionpertains, unless otherwise defined. In some cases, terms with commonlyunderstood meanings are defined herein for clarity and/or for readyreference, and the inclusion of such definitions herein should not beconstrued to represent a substantial difference over what is generallyunderstood in the art. The techniques and procedures described orreferenced herein are generally well understood and commonly employedusing conventional methodologies by those skilled in the art, such as,for example, the widely utilized molecular cloning methodologiesdescribed in Sambrook et al., Molecular Cloning: A Laboratory Manual3rd. edition (2001) Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N.Y. and Current Protocols in Molecular Biology (Ausbel et al.,eds., John Wiley & Sons, Inc. 2001. As appropriate, procedures involvingthe use of commercially available kits and reagents are generallycarried out in accordance with manufacturer defined protocols and/orparameters unless otherwise noted.

Overview of LFM System

The invention relates to miniaturized lateral flow chromatographicmethods and devices useful for the sensitive and specific detection ofnucleic acid and protein analytes. As the invention realizes many of thebenefits of microarray technology, incorporated into a lateral flowtechnology platform, the term “lateral flow microarray” or “LFM” is usedherein. Principal features of LFM include small feature sizes (spotsizes) compared to traditional lateral flow devices (i.e., typicallyless than 600 μm diameter, more typically less than 300 μm diameter, andin some embodiments, smaller, i.e., 50 μm diameter or less), reducedwidth of the microporous detection membrane, high feature densitypotential, and multiplex capability. These features, in turn, result inlower sample volume requirements (i.e., 10 μL), faster assay run times,lower reagent costs, and surprising levels of sensitivity (i.e.,attomolar) and linear dynamic range (i.e., 3 orders of magnitude signallinearity).

The sensitivity of lateral flow nucleic acid detection methodspreviously reported in the literature has been on the order of 1 fmol(e.g., (25)). In embodiments of LFM which utilize dyed polystyrenemicrospheres as the detection particle (i.e., colorimetric detection),the LFM platform provides rapid detection of as little as 250 amol oftarget using a low cost and widely available flatbed scanner, a standardpersonal computer system and a commercially available microarray dataextraction suit or free image analysis software. This detection limit issimilar to the sensitivity reported for fluorescence andchemiluminescence microarray detection strategies (9,46). Furthermore,it is likely that the sensitivity of LFM may be improved by usingsemi-conductor nanocrystal as the detection particle. Importantly,utilizing nanocrystals in LFM assays results in improved linear dynamicrange (see Examples, infra).

LFM demonstrates excellent linear dynamic range utilizing dyedmicrospheres as the detection particle. Indeed, with reference to thestudies described in Example 6, infra, the effective linear range of theLFM assay extends over a 400-fold range of target from 250 amol to 100fmol (see FIGS. 9B and 9C). As the information density of the LFM offersthe capacity for additional capture probes of varying hybridizationpotential to be included, it is expected that this dynamic range may beextended. The uniformity of sample flow exhibited by the LFM suggeststhat larger capture probe sets can be accommodated without complicationsarising from physical factors. For example, concentrations of analyte40-fold above the linear range of R-77-96 did not adversely impact thelinearity of R-24-43 signal at LFM elements situated directly downstream(with respect to sample flow) of R-77-96 capture features (FIGS. 9B and9C). Only at artificially high microsphere capture densities, such asthose produced by the positive control hybridizations in FIG. 8, aresignal gradients observed as a function of physical location on the LFM,presumably due to physical occlusion of membrane pores by high localaccumulations of microspheres.

Studies utilizing semi-conductor nanocrystals as the detection particleindicate that the linear dynamic range of LFM may be improved to atleast three orders of magnitude. As shown in Example 8, remarkablesignal linearity over the 1 fmol to 1000 fmol range of dnaR89 analytewas achieved using LFM devices containing nanocrystal-conjugateddetection oligonucleotides (R²=0.991).

LFMs offer several advantages arising directly from the miniaturizationof the system without sacrificing detection sensitivity. Whiletraditional lateral flow assays make use of sample volumes on the orderof hundreds of microliters to milliliters, the miniaturization approachembodied in the invention reduces sample volume to about 10 μl. Thisreduced sample volume significantly decreases the consumption ofreagents required for amplification, and thus assay cost. In theExamples disclosed herein, the LFM device enabled a reduction in thestandard NASBA reaction volumes from 20 μl to 2 μl, thereby achieving aone order of magnitude reduction in enzyme consumption. Similarly, otheramplification schemes, such as those that make use of microfluidicsystems or lab-on-a-chip technologies, may be integrated with LFM-baseddetection systems to provide a rapid and cost effective means ofdetecting analytes.

A further benefit of LFM is the time required to detect analytefollowing introduction of amplified sample material. While theprocedures used in Example 8 employed NASBA amplification andtraditional RNA isolation protocols requiring approximately 90 minutesto complete, more recent advances in nucleic acid preparation andamplification have reported significant reduction in sample processingtimes (for a recent review see (47)). As amplification protocols becomemore rapid, the speed with which amplicons can be detected, withoutreliance on complex optical systems and fluorescent detection methods,will be critical to realizing the potential of these technologies. TheLFM methods of the invention are able to achieve detection of nucleicacid analytes in less than 2 minutes. Given that 250 amol is equivalentto 1.5×10⁸ molecules, efficient amplification methods that offer 10⁹fold amplification, widely cited amplification levels for PCR- andNASBA-based techniques (22,48), would theoretically enable the detectionof single copy targets by LFM following amplification. Future systemsthat couple advanced amplification technologies and compatiblestreamlined nucleic acid preparation modalities with rapid LFM detectionwill allow significant decreases in sample-to-answer times withoutcostly or complex instrumentation.

LFM devices of the invention utilize sandwich-type hybridization, eitheremploying sets of target-complementary oligonucleotides (or othernucleic acid molecules, such as dendrimers) to detect nucleic acidanalytes, or binding ligands such as antibodies to detect proteinanalytes. In respect of nucleic acid detection methods using LFM,nucleic acid target is detected redundantly using (a) detectably labeleddetection oligonucleotides complementary to one of two signaturesequences on the target nucleic acid (i.e., oligonucleotides conjugatedto a detectable label, such as dyed microspheres, semi-conductornanocrystals, etc.), and (b) membrane-immobilized captureoligonucleotides complementary to the other signature sequence on thetarget. In the practice of a nucleic acid detection assay utilizing theLFM system of the invention, the capture of amplified target nucleicacids by the membrane-immobilized capture oligonucleotides and labeleddetection oligonucleotides brings the label into contact with themembrane, displaying a visual or machine-readable optical signal. Thus,the assay requires positive hybridization to two distinct sequences onthe target nucleic acid in order to produce a localized signal,resulting in very high assay specificity.

Physical Components of LFM Devices

The lateral flow chromatographic devices of the invention comprise aseries of absorbent substrates which are used to transport analyte in alateral manner to components containing certain reagents or materialsrequired for the detection of the analyte.

In one aspect, a lateral flow chromatographic device of the inventioncomprises a chromatographic test strip which comprises (a) a samplereceiving zone for receiving an aliquot of the sample and for receivinga labeled detection oligonucleotide, which detection oligonucleotidecomprises a sequence which is complementary to a first sequence of thetarget nucleic acid; and, (b) a capture zone in lateral flow contactwith the sample receiving zone, said capture zone comprising amicroporous membrane, onto which at least one capture oligonucleotide isimmobilized and which comprises a sequence which is complementary to asecond sequence of the target nucleic acid. In an alternativeembodiment, a labeling zone in lateral flow contact with said samplereceiving zone is inserted up-stream of the capture zone and is lateralflow contact with the capture zone. A labeling zone comprises a porousmaterial containing at least one detection oligonucleotide reversiblybound thereto, which detection oligonucleotide is complementary to afirst sequence of the target nucleic acid and is coupled to a detectablelabel, thereby enabling the label step to take place on the device.

In a simplified illustration, one embodiment of the LFM device isstructurally organized into at least 3 zones, comprising in linearorientation: (a) a sample pad constructed from absorbent material ontowhich a liquid, nucleic acid-containing sample is deposited, (b) aconjugate release pad containing a least one oligonucleotide-fitteddetection particle (e.g., microsphere, bead, quantum dot), and (c) adetection zone comprising a nitrocellulose or nylon membrane containingat least one immobilized capture oligonucleotide. In some embodiments, afourth element comprises an absorbent material which is capable offacilitating the lateral flow of the liquid sample from the sample padend of the device to and through the detection zone. In someembodiments, the sample pad (a) and the conjugate release pad (b) arecombined. In alternative embodiments, the conjugate release pad elementis eliminated, and the sample to be assayed for the presence of a targetnucleic acid is mixed with the oligonucleotide-fitted detection particleprior to placing the sample onto the sample pad.

The first substrate, or sample pad or sample receiving zone, comprisesan absorbent material preferably composed of a matrix, with minimalnucleic acid binding properties, that will permit unobstructed migrationof the nucleic acid analyte to subsequent stages of the apparatuswithout depletion. In a specific embodiment, the sample pad is composedof a cellulose fiber pad such as Millipore cellulose fiber sample padmaterial (Cat# CFSP223000).

In embodiments where separate sample and conjugate release pads areemployed in the LFM device, the sample pad is situated within the devicesuch that it is in physical contact with the conjugate release pad.

The substrate which contains the labeled detection oligonucleotideconjugate is termed the conjugate release pad or labeling zone. In someembodiments, the labeling zone is also used to receive sample directly.The conjugate release pad comprises a matrix composed of a material withminimal nucleic acid binding capacity and of a physical compositionwhich allows dried detection particles to be liberated into solutionwith minimal residual binding to the matrix. Examples of materialssuitable for conjugate pads include glass fiber and polyester materials(e.g., rayon). These materials are commonly available from variouscommercial sources (e.g., Millipore, Schleicher & Schuell).

The detection membrane of the capture zone may be any microporousmembrane material which is lateral flow compatible, typicallymicroporous cellulose or cellulose-derived materials such asnitrocellulose (e.g., HiFlow 135, Millipore) or nylon. In someembodiments, the sample receiving zone and the capture zone comprise acontiguous microporous membrane.

Typically, the microporous membrane defines a relatively narrow flowpath. This may be achieved, for example, by utilizing narrow strips ofmicroporous membrane material. Excellent results are obtained withmembrane strips of 5 mm or less in width, with the best results beingobtained with strips of 3 mm or less. As will be appreciated, othermeans for retaining a narrow flow path of less than 5 mm or less than mmmay be used, and may include without limitation the use of barrierswhich define borders which limit the flow path to a channel.

The microporous membrane of the capture zone is a lateral flowcompatible membrane such as cellulose, nitrocellulose, polyethersulfone,polyvinylidine fluoride, nylon, charge-modified nylon, andpolytetrafluoroethylene. Typically, the membrane is nitrocellulose. Thedetection membrane is typically provided with a backing material forsupport, such as mylar or similar plastic materials. The membrane may betreated with agents that inhibit non-specific binding of analyte orother reagents used in an LFM assay.

In embodiments utilizing nitrocellulose, pore sizes typically rangebetween 0.2 and 20 μm, and more typically between 0.2 and 12 μm. Inpreferred embodiments utilizing particle labels, the pore size of themicroporous membrane should be on the order to about 10 times thediameter of the particle.

In one embodiment, the detection membrane is composed of a supportednitrocellulose membrane of sufficiently large pore structure to allowthe unimpeded transport of detection reagent through the membranematrix. Examples of suitable nitrocellulose materials for dyedmicrosphere mediated detection are Millipore HiFlow Plus HF09004,HF13504, Schleicher & Schuell Prima 60, Schleicher & Schuell Prima 85.The Millipore HF13504 nitrocellulose membrane has been demonstrated toprovide rapid, specific and sensitive detection when patterned withappropriate capture oligonucleotides (see Examples, infra). Themicroporous membrane is placed in lateral flow contact with the labelingzone (conjugate release pad).

In some embodiments, an absorbent material is placed in lateral flowcontact with the distal end of the detection membrane in order tofacilitate lateral flow through the entire LFM device. Materialssuitable for use as an absorbent pad include any absorbent material,including, but not limited to, nitrocellulose, cellulose esters, glass(e.g., borosilicate glass fiber), polyethersulfone, cotton, dehydratedpolyacrylamide, silica gel, and polyethylene glycols. The rate ofcapillary flow can be controlled by choosing the appropriate absorbentzone material.

LFM devices may be encased in a housing as described in, e.g., U.S. Pat.No. 5,451,504. Materials for use in the housing include, but are notlimited to, transparent tape, plastic film, plastic, glass, metal andthe like. Such housings preferably contain an opening or sample port forintroducing sample, as well as a window(s) permitting the visualizationof the detection zone(s) of the detection membrane.

Microarray Fabrication:

In the fabrication of an LFM device, the microporous membrane of thecapture zone is used for patterning capture oligonucleotides and orprotein capture ligands (i.e., antibodies).

In preferred nucleic acid detection LFM fabrications, captureoligonucleotides are patterned onto the detection membrane or substrate(i.e., nitrocellulose) with spot diameter sizes (“feature sizes”) ofabout 1 mm or less, preferably 600 μm or less, more preferably less thanabout 300 μm diameter, and in some embodiments, smaller (i.e., 50 to 200μm, 50 to 250 μm, 50 to 300 μm). Oligonucleotide concentrations forspotting are generally in the range of 200 μM-800 μM. In embodiments inwhich PNAs or LNAs are used to synthesize oligonucleotides, lowerdensities may suffice.

Detection membranes may be patterned to suit the desired design of thedetection element of the device. Methods for depositing nucleic acidsand proteins onto microporous membranes such as nitrocellulose are wellknow, and negative and positive control reagents as well as capturereagents may be patterned on to the detection membrane using any of anumber of deposition techniques. These techniques can be selected basedon the density of information to be represented on the detectionmembrane. Manual deposition by pipette, automated deposition by roboticsthrough contact mediated processes (stainless steel pins on a contactmicroarray printing robot) or noncontact mediated processes such aspiezo responsive micropipettes, may all be used successfully tofabricate the nucleic acid detection device described here.

Preferably, when using nitrocellulose and similar membranes, non-contactprinting techniques are used to deposit capture oligonucleotides orproteins onto the detection membrane, in order to retain the structuralintegrity of the detection membrane material. See. For example, thenon-contact printing methods utilized in the Examples which follow.

Additionally, more convention means may be employed, including varioustechniques commonly used to fabricate hand held assay devices for theimmunological detection of proteinaceous analytes in the context of alateral flow immunochromatographic device.

For example, immobilization of capture oligonucleotides directly on thedetection membrane may be accomplished by using high salt to adsorb thenucleic acid molecules to the surface of the membrane, combined withbaking at about 80° C. to permanently fix the adsorbed oligonucleotides.Additionally, oligonucleotides may be deposited onto the membrane (i.e.,nitrocellulose), air dried, and subjected to UV radiation (see Examplesherein). Capture oligonucleotides may also be fixed directly todetection membrane by vacuum transfer in the presence of an equimolarconcentration of sodium chloride and sodium citrate, or by the use ofultraviolet irradiation. The capture oligonucleotides may also becovalently linked to charge-modified nylon. In other embodiments,capture oligonucleotides may incorporate a reactive ligand (e.g.,biotin) and may be immobilized indirectly on the detection membrane as aresult of the interaction between the ligand and an immobilized memberof a binding pair (e.g., streptavidin).

Detection membranes may be patterned with positive and negative controlreagents and capture reagents in an array such that the physicalposition of each reagent is known. Positive control reagents can becomposed of oligonucleotides complementary to detection oligonucleotidesimmobilized on detection reagents (i.e. dyed microspheres linked tooligonucleotides through a covalent bond or through an affinityinteraction such as that mediated by streptavidin/biotin interactions).Alternatively, in embodiments where the streptavidin/biotin interactionis used to couple dyed microspheres to oligonucleotides the positivecontrol array element can be composed of biotin in any of a number offorms suitable for immobilization on nitrocellulose (for example, abiotin labeled nucleic acid). Following binding to detectionoligonucleotides, free biotin binding sites on streptavidin-conjugateddyed microspheres remain available for interaction with immobilizedbiotin on the detection membrane, thus providing one form of positivecontrol.

Another positive control may be achieved by the immobilization ofoligonucleotide on the detection membrane. The use of an oligonucleotidecomplementary to the dyed microsphere-conjugated detectionoligonucleotide as a positive control allows direct hybridization of thedetection oligonucleotide/dyed microsphere complex following lateralflow chromatography over the positive control. Negative controls forhybridization specificity can be incorporated into the device bypatterning the detection membrane with detection oligonucleotide orother nucleic acid sequences predicted, by means known to those skilledin the art, to not hybridize to the detection oligonucleotide sequence.

For nucleic acid analytes, capture reagents are composed ofoligonucleotides synthesized such that the sequence is complementary toa region of the analyte target nucleic acid not overlapping with theregion complementary to the detection oligonucleotide. Ideally, thepredicted secondary structure of the analyte target nucleic acid isexamined to identify those regions exhibiting reduced likelihood ofparticipating in intramolecular hydrogen bonds. Such regions arepreferable sites for detection and capture oligonucleotide binding.

Array elements may take the form of lines, stripes, dots or humanreadable icons, letters or other forms or shapes deemed useful to theinterpretation of device read-out. In the case of spots or dotsdeposited by robotic or manual means, individual feature sizes from 50microns to 5 mm have been shown to provide accurate and interpretablehybridization mediated detection of 20 fmol analyte DNA molecules.

Capture and Detection Oligonucleotides:

For nucleic acid analytes, LFM devices incorporate two classes ofoligonucleotide referred to here as capture and detectionoligonucleotides. The detection oligonucleotide is linked by any of anumber of means to a detection reagent or label that, when concentratedby capture through hybridization, renders the capture zonedistinguishable (i.e., opically) from the surrounding substrate and fromadditional capture zones where the detection reagent has not beensequestered. Examples of detection reagents include polystyrenemicrospheres, latex particles, nano-gold particles, colloidal goldparticles, metal particles, magnetic particles, fluorescently detectableparticles, and semi-conductor nanocrystals and the like.

Alternatively, a nucleic acid complex, such as a DNA dendrimer orbranched-DNA molecule, carrying multiple detectable moieties, such asfluorescent molecules or biotin, can be used to amplify lateral flowmicroarray signal intensity. By generating DNA dendrimers carrying adetection sequence complementary to a region of the target (detectionsequence) each hybridization event at the LFM capture zone results inthe localization of multiple detectable labels. Using a highlybiotinylated dendrimer and a streptavidin conjugated detection particlesuch as a dyed microspheres or semi-conductor nanocrystals, bothcalorimetric and fluorescent signal amplification can be realized. Forexample, the large number of streptavidin binding sites on biotinylateddendrimers will increase the number of streptavidin bound particlescaptured by each hybridization event and generate a correspondinglyamplified signal. Several potential advantages, especially with respectto multiplexed detection, may be realized using this approach.Specifically, the use of a generic biotin/streptavidin interactionallows the simultaneous use of multiple detection probe sequenceswithout requiring the preparation of multiple quantum dot-detectionprobe conjugates. Together with the use of generic tag sequences addedto amplicons through the use of specially designed NASBA primers, thisapproach is compatible with the development of generic tag-based LFMssuitable for the detection of differing panels of pathogens withoutredesign of the LFM layout.

The detection oligonucleotide is designed such that the meltingtemperature of the resulting oligonucleotide allows hybridization to itscognate sequence on the analyte under ambient conditions with sufficientrapidity to allow duplex formation to occur during lateral flow.Detection oligonucleotides with Tm of 50-70° C. have been shown toprovide effective reagents for the detection of relevant analytes (usingapproximately 20-mer oligonucleotides).

Detection oligonucleotides are synthesized with suitable modificationsto allow the efficient linkage to appropriate detection reagent. In someembodiments it is advantageous to include a spacer sequence consistingof 9 to 20 T residues proximal to the modified end of theoligonucleotide that will be coupled to the detection reagent.Chemistries of known suitability for use in the device includebiotin/streptavidin through a biotin incorporated onto either the 5′ or3′ end of the detection oligonucleotide and covalent cross-linkingthrough a primary amine incorporated into either the 3′ of 5′ end of thedetection oligonucleotide. In one preferred process, detectionoligonucleotides are covalently linked to polystyrene microspheres usingthe coupling agent 1-etyl-3-(3-dimethylaminopropyl-diimide HCl (EDAC).Other methods that mediate the formation of a stable complex between thedetection reagent and the detection oligonucleotide under assayconditions should also be suitable for use in the fabrication of thedevice.

The second class of oligonucleotide used in the device is the captureoligonucleotide. This reagent is immobilized on the microporousdetection membrane through the use of standard methods for couplingnucleic acids to nitrocellulose or nylon, including without limitationdrying followed by ultraviolet light cross-linking using 0.5 Joules UV.The capture oligonucleotide is designed such that the sequence iscomplementary to the analyte target nucleic acid at a region predictedto have little or no secondary structure. The length of the captureoligonucleotide is typically approximately 20 bases in length or of alength to generate a predicted melting temperature of approximately50-70° C.

In some embodiments it may be advantageous to add a spacer sequenceconsisting of 9 to 20 T residues.

Detection and capture oligonucleotides can be synthesized using wellknown DNA synthesis chemistries. The incorporation of modified nucleicacids such as PNA (peptide nucleic acid) or LNA (locked nucleic acid)may be useful for the enhanced hybridization properties of these DNAderivatives. The use of PNA or LNA moieties in the preparation ofdetection and/or capture oligonucleotides will be useful in manipulatingthe desired melting temperature, and so may allow shorteroligonucleotides to be employed for detection and/or capture wheresequence constraints preclude longer DNA oligonucleotides.

In some embodiments, detection and capture oligonucleotides are designedto hybridize to target nucleic acid within 0, 1 or 2 bases of eachother, in order to increase the stability of hybridization via the “basestacking” phenomenon. Base stacking has been reported to stabilizehybridization and allow efficient capture of dilute nucleic acids byhybridization (38-42). The data generated in Example 6, infra,demonstrates that detection and capture oligonucleotides which bind intandem result in significantly higher hybridization signals.

Detection Modalities:

The detection zone (detection membrane) of the lateral flow device maycomprise one or more capture oligonucleotides which are complementary toone or more target sequences. The capture oligonucleotides are stablyaffixed to the sample-exposed surface(s) of the microporous detectionmembrane using standard methodologies. Protein capture reagents may alsobe patterned onto the detection membrane using standard methods.

The LFM devices of the invention can make use of diverse detectionmodalities, including visual detection signals resulting from thecapture and increased local concentration of an appropriate detectionparticle. The resulting colorimetric signal can be visualized by eye.Alternatively, for more quantitative and sensitive detection of signal,an electronic instrument capable of detecting calorimetric signals maybe employed. Such instruments include standard flatbed scanners,dedicated lateral flow chromatographic strip readers (e.g. QuadScan, KGWEnterprises, Inc), or a simple CCD based devices fabricated for thedetection of calorimetric signals such as those employed by commerciallyavailable immunochromatographic test strips (e.g. Clearblue Easy DigitalPregnancy Test).

Visualization by eye can be aided by the fabrication of the device in amanner that generates an easily recognized or interpreted shape on thedipstick surface. One example would be the patterning of an LFM withelements in a physical configuration that results in the appearance of aletter or symbol indicative of a positive or negative result (e.g. a “+”or “−” symbol).

Embodiments that employ fluorescent detection reagents such asfluorescent nanoparticles (e.g. Qdots, QuantumDots, Inc.) offer thepotential increased sensitivity that results from the application offluorescence detection technology. Such embodiments can be read usingany of a number of ultraviolet light sources including hand held UVlamps, UV emitting LEDs, and light sources with sufficient emission inthe UV to excite the nanoparticles. A simple filter can be used toenhance the visualization of nanoparticle fluorescence emissions. Forexample, a long pass filter with a cut off below the emission wavelengthof the nanoparticle may be employed. In the case of excitation with awhite light source, an additional filter to limit excitation to UVA andshorter wavelengths can be used (e.g., a 380 nm short pass filter).

The microporous detection membrane may contain capture oligonucleotidesprinted monolithically in order to produce virtually any calorimetricpattern that can be visualized by the unaided human eye, such as bands,letters, numbers, symbols, and the like. If the sample contains both thefirst and second target sequences, colored beads with hybridizeddetection oligonucleotide-target nucleic acid will then hybridize to theimmobilized capture oligonucleotide, and thereafter remain stablyimmobilized to the membrane at that physical location. Such “lowdensity” components of the detection zone may be used to provide a rapidindication of the presence of a target sequence or sequences in thesample, visualized only be the unaided eye.

In addition, the capture zone may contain one or more “high density”components, capable of providing high resolution detail of thesignatures of the sequences present in the sample nucleic acid. Forexample, an array of a number of distinct second detectionoligonucleotides may be deposited in distinct physical locations on themembrane (i.e., an array of spots), each of which detectionoligonucleotide is specifically complementary to a distinct targetsequence. Such high-density arrays may be used to interrogate the samplefor genotype signature sequences and the like. These array componentsmay be read by methods well known in the art, including by scanning andcomputer assisted densitometry, the use of CCD cameras, etc.

Assay devices of the invention comprising such low and high densitydetection zones are termed “dual-density” systems, assays and devices.The principal design element of such dual-density devices is theprovision of two levels of information obtained from a single sample.The low density component provides instantaneous visual informationindicative of the presence or absence of a first level target sequence,and may be used to provide fundamental diagnostic information, such asthe presence of a nucleic acid sequence indicative of a virus orbacteria in the sample. Because this information is provided by acolored band or other shape or symbol, the user is able to identify thepresence of a target immediately and without the use of anyinstrumentation whatsoever.

The high density components may be assayed using standardinstrumentation at any time following the assay. For example, the devicemay be stored or shipped for high density array analysis usingappropriate instrumentation and/or expertise. Thus, as an example, suchdual-density devices may be used by a consumer patient for determiningwhether a body fluid sample contains an influenza virus. A positiveresult indicates the need for having the high density component of thedevice analyzed by specialized personnel, in order to determine theinfluenza strain, subtype, or genotype, for example. The consumerpatient is able to use the device to determine the need for professionmedical attention. The medical professional is able to analyze the samedevice for more specific diagnostic information.

LFM Nucelic Acid Assays:

In one aspect of the invention, an LFM assay is provided. LFM assays ofthe invention are useful for the specific detection of a target analyte,typically from a complex sample of interest, and generally comprise thesteps of extracting analyte material (i.e., DNA, RNA, protein) fromsample of interest, enriching for the analyte, and detecting thepresence of the analyte using an LFM device populated withtarget-specific capture elements.

In one aspect, the invention provides a method of testing for thepresence of a target nucleic acid in a liquid sample, comprisingapplying or contacting the liquid sample to the sample receiving zone alateral flow chromatographic device of the invention, allowing thesample to transport by capillary action through the capture zone, anddetecting the presence or absence of the target nucleic acid bydetecting the presence of the label at the relevant capture zonefeature.

Various DNA and RNA extraction methodologies are routine and well knownin the art. Various kits for the efficient extraction of total nucleicacid, RNA or DNA are widely available from a number of commercialentities. Any of these methodologies and kits may be used to extractnucleic acid from a sample to assessed using the LFM assay.

Single-stranded RNA or DNA targets may be amplified directly, whiledouble-stranded DNA targets generally are rendered single-strandedbefore amplification. Methods for rendering single-stranded DNAtemplates from a double-stranded DNA targets include without limitationheat penetration (i.e., 95° C. for 5 minutes) and chemical denaturation(i.e., sodium hydroxide, followed by neutralization). Another method forrendering amplifiable single-stranded DNA from double-stranded DNAinvolves enzymatic unwinding of the double-stranded DNA, using forexample a DNA helicase, which can open-up portions of the DNA,permitting primer and polymerase access and binding (see Kornberg andBaker, 1992, DNA Replication, 2nd edn, New York: WH Freeman and Company;Caruthers and McKay, 2002, Helicase structure and mechanism. Curr OpinStruct Biol 12: 123-133).

As used herein, a “target sequence” is a nucleotide sequence within atarget nucleic acid molecule which is to be amplified. Within the targetsequence is a primer binding portion, to which primers are designed tohybridize in order to initiate DNA polymerization.

The selection of a particular target sequence for amplification willrelate to the LFM assay objectives. For example, where amplification isaimed at identifying a particular strain of an organism, the targetsequence should be one of the unique genetic signatures whichdifferentiates that strain from others to which it may be related. Insome cases, this may be a single defining sequence. In other cases, acombination of target sequences may be required to reliably identify anddifferentiate the organism. The selection of target sequences whichimpart specificity to assays utilizing amplified genetic materialinvolves considerations well known in the art, including for example,unique pathogen-specific sequences, toxins genes, virulence factors orspecific signature sequence combinations.

In the practice of the invention, single or multiple target sequencesmay be amplified in a single reaction using suitable, specific primeroligonucleotides. When multiple target sequences are to be amplified,primers must be designed to avoid possible nonspecific interactions asis well known.

Extracted nucleic acids may be purified prior to amplification. A numberof column type DNA and RNA purification devices are commerciallyavailable and may be employed for this purpose. Various other techniquesfor purifying DNA and RNA may be employed, including without limitation,electrophoresis, gradient separation, affinity purification, etc.

LFM assays are useful for the detection of single stranded amplificationproducts derived from samples of interest (i.e., clinical samples,environmental specimens, etc.). LFM is compatible for use with virtuallyany nucleic acid amplification method. In the context of the rapid,simplified and highly sensitive LFM assays of the invention, LFMs areparticularly intended for use with isothermal amplificationtechnologies. In one embodiment, extensively characterized herein by wayof the several Examples which follow, the isothermal amplification NASBAis utilized. NASBA-amplified target nucleic acids are detected at veryhigh specificity in a matter of seconds.

NASBA is an RNA amplification methodology that offers several advantagesover other RNA amplification methods, including the absence of a reversetranscriptase step. NASBA is an isothermal reaction performed at 41° C.,which obviates the need for a thermocycler and may facilitate theproduction of point-of-test devices. A single-stranded antisense RNAproduct is produced during NASBA, which can be directly hybridized by aprobe sequence to accelerate post-amplification interrogation of theproduct. Additionally, selection criteria for NASBA primers are lessstringent than with other amplification methods, allowing easier primerdesign in selected less-conserved regions of the gene. Furthermore, theamplification power of NASBA has been reported to be comparable to, orsometimes even higher than that of PCR.

In this connection, the invention provides a method for detecting thepresence of a target nucleic acid in a biological sample, comprising:(a) providing a biological sample suspected of containing the targetnucleic acid sequence; (b) releasing nucleic acid from the biologicalsample; (c) amplifying the target nucleic acid using nucleic acidsequence based amplification (NASBA) to generate a solution containingamplified single-stranded RNA complementary to the target nucleic acid,if present in the extracted DNA and/or RNA from the biological sample;and, (d) assaying for the presence of the complementary RNA targetnucleic acid using the method according to claim 27.

In the LFM assay progression, initially, and typically followingextraction and amplification of target nucleic acid, a solutioncontaining one or more target sequences to be detected by the device isintroduced to the sample pad. This may be achieved by dipping thelateral flow device sample pad/sample receiving zone into the solution,or by dropping a quantity of the solution onto the sample pad/samplereceiving zone of the lateral flow device. The device is sufficientlyrobust that the composition of the buffer solution carrying the targetsequence(s) is not critical, however, several practical considerationsare taken into account to assure compatibility of the buffer with thedevice. Most significantly, the ionic strength of the sample buffer mustbe such that precipitation or aggregation of the detection particlesdoes not occur. Similarly, sufficient ionic strength of the buffer isrequired to support hybridization during lateral flow. Impregnation ofthe sample pad and/or conjugate release pad with Triton-X100, SDS, BSA,ficol, and/or polyvinyl pyrolidone, or introduction of these componentsto the sample buffer itself, can stabilize the detection particles andblock non-specific interactions between the detection particles and thedetection membrane. While a range of concentrations of these reagentscan be used successfully, buffers of proven efficacy include 0.1% ficol,0.1% BSA, 1% Triton X-100, and 150 mM NaCl. This particular buffersupports mono-disperse detection particle suspensions.

Additionally, buffers containing higher concentrations of Triton X-100and SDS have been found to support higher ionic strength environmentswithout detection particle aggregation and may be used to facilitatehybridization. For example, 3% Triton X-100, 0.1% SDS, 600 mM NaCl hasbeen shown to support subnanomolar hybridization-based detection on thedevice.

Optimized buffer, reagent parameters and coupling protocols for LFMdevices utilizing nitrocellulose detection membranes are presented inExample 5.

Once on the sample pad/sample receiving zone, the analyte solution flowsfrom the proximal (sample) end towards the distal (detection) end of thedevice. In one embodiment, detection oligonucleotide-functionalized dyedmicrobeads are embedded into the conjugate release pad component of thedevice, preferably in lyophilized form, ready to be re-hydrated as theanalyte solution travels into this area of the device. As the analytesolution moves across the conjugate release pad, the microbeads arerehydrated and are available for detection oligonucleotide hybridizationto target sequences within the sample. Target sequences, when present,will become hybridized to the detection oligonucleotide and thus to thebeads. This complex continues lateral flow migration to the detectionmembrane, where immobilized capture oligonucleotides hybridize to thetarget sequence, thus capturing the target sequence-bead complex.

The invention also provides lateral flow chromatographic microarraydevices. In one aspect, for example, the invention provides a lateralflow microarray chromatographic device for detecting the presence orabsence of a plurality of single-stranded target nucleic acids in one ormore fluid samples, comprising a lateral flow matrix which defines aflow path and which comprises in series: (a) a sample receiving zone forreceiving the fluid sample(s); (b) a labeling zone in lateral flowcontact with said sample receiving zone, wherein the labeling zonecomprises a porous material containing a plurality of differentdetection oligonucleotides reversibly bound thereto, which detectionoligonucleotides are complementary to first sequences of a plurality ofrespective target nucleic acids and are coupled to detectable labels;and, (c) a capture zone in lateral flow contact with said labeling zone,said capture zone comprising a microporous membrane, at least a portionof which contains a plurality of different capture oligonucleotidesimmobilized thereto, which capture oligonucleotides are complementary tosecond sequences of a plurality of respective target nucleic acids, andwherein the different capture oligonucleotides are immobilized to themicroporous membrane at a feature size of 300 μm or less in diameter.

Another aspect is drawn to lateral flow chromatographic microarraydevices which eliminate the labeling zone. For example, the inventionprovides A lateral flow microarray chromatographic device for detectingthe presence or absence of a plurality of target nucleic acids in one ormore fluid samples, comprising a lateral flow matrix which defines aflow path and which comprises in series: (a) a sample receiving zone forreceiving the fluid sample(s) and for receiving a plurality of differentdetection oligonucleotides, each of which detection oligonucleotidescomprises a sequence which is complementary to a first sequence of aspecific target nucleic acid and is labeled; and, (b) a capture zone inlateral flow contact with said labeling zone, said capture zonecomprising a microporous membrane, at least a portion of which containsa plurality of different capture oligonucleotides immobilized thereto,each of which capture oligonucleotides comprises a sequence which iscomplementary to second sequence of the specific target nucleic acid,and wherein the different capture oligonucleotides are immobilized tothe microporous membrane at a feature size of 300 μm or less indiameter.

Kits are also provided. In aspects in which the labeling zone iseliminated, thereby requiring the addition of a labeled detectionoligonucleotide, the invention provides a kit for testing the presenceof a target nucleic acid in a sample, comprising: (a) a lateral flowchromatographic device or lateral flow chromatographic microarray deviceof the invention, and (b) a labeled detection oligonucleotidecomplementary to a second sequence in the target nucleic acid.

LFM, LFM assays and LFM devices of the invention are further describedby way of the following examples, none of which are intended to belimiting.

EXAMPLES Example 1 Detection of DNA Hybridization Over Broad Range ofCapture Oligonucleotide Deposition Concentrations on DNA Dipstick

DNA dipstick microarrays were fabricated at a density of 36 features permm² using varying concentrations of capture oligonucleotide, asindicated In FIG. 1. Printing solutions of capture oligonucleotide at200 μM, 100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, and 3.125 μM wereprepared and patterned on to lateral flow membranes. The resulting DNAdipstick microarrays were introduced to 100 μl of synthetic target DNAat the indicated concentration of 1 μM, 100 nM, 10 nM, 1 nM, and 0 nMcorresponding to 100 μmol, 10 μmol, 1 μmol, 100 fmol, and 0 fmol targetmolecules respectively. Capture of 100 fmol target molecule was apparentat capture oligonucleotide printing concentrations as low as 12.5 μM(FIG. 1). However, the most sensitive detection was obtained at highercapture oligonucleotide printing concentrations of 200 μM. SubsequentDNA dipsticks and DNA dipstick microarrays were fabricated using 200 μMsolutions of capture oligonucleotide. These data demonstrate that DNAdipstick microarrays provide robust hybridization based detection overan order of magnitude range of capture oligonucleotide depositionconcentrations. This further suggests that fabrication of DNA dipstickmicroarrays will be relatively insensitive to variations in captureoligonucleotide concentration resulting from varying synthesisefficiencies.

Example 2 Detection of Single and Multiple SS-DNA Species

The following example demonstrates sensitive detection ofsingle-stranded DNAs using hybridization-based capture anddyed-microsphere calorimetric detection.

Sequences derived from the B. anthracis pagA, capB and cya genes wereused to demonstrate multiplexed detection. DNA Dipsticks were patternedwith capture sequences for the detection of fragments of three keyvirulence factors of B. anthracis.

The capture sequences used were:

pagD: [SEQ ID NO: 7] 5′- GCAGGATTTAGTAATTCGAATTTTTTTTTTTTTTT-3′;cyaD908: [SEQ ID NO: 8]; 5′ TGGTACTAAACCTGAAGCTTTTTTTTTTTTTTTTT 3′; andcapD: [SEQ ID NO: 9] 5′-TACATGGTCTTCCCAGATAATTTTTTTTTTTTTTT-3′.0.35 μm dyed COOH microspheres (Spherotech, Inc.) were coupled usingEDAC and standard protocols to:

[SEQ ID NO: 10] 5′ amine-C12-TTTTTTTTTTTTTTTTTTCAGAAGAATTCTTACGAAAATTTGAT 3′ for capB detection, [SEQ ID NO: 11]5′ amine-C12-TTTTTTTTTTTTTTTTTCTTTGATATTGGTGGGAGTG TATC for pagAdetection; and [SEQ ID NO: 12]5′ amine-C12-TTTTTTTTTTTTTTTTTAAAAGCATCTGCATGTTC for cya detection.

Populations of beads coupled independently to these detection sequenceswere pooled for use as colorimetric labels in hybridization-basedlateral flow detection assays. The results are shown in FIG. 2, anddescribed in the description of FIG. 2. These data demonstrate rapid,specific and sensitive multiplexed hybridization-based detection in alateral flow device.

Example 3 Sensitivity and Detection Time for DNA Dipstick and DNADipstick Microarray

The sensitivity and time required to detect nucleic acids on DNAdipsticks and DNA dipstick microarrays were evaluated using synthetictarget molecules for which exact concentrations could be determined.

Dipsticks were fabricated by manual deposition of captureoligonucleotides onto membrane strips of approximately 160 to 275 mm²surface area, features sizes were ˜2-3 mm in diameter. Dipstickmicroarrays were printed using microarray fabrication robotics topattern membrane strips of approximately 60 mm² surface area such thatfeature sizes were 300-600 μm in diameter. DNA dipsticks were challengedwith 400 μl of synthetic target molecule in the presence of appropriatedetection microspheres. Typical lateral flow time for these strips wasapproximately 45 minutes from sample introduction to complete transportof the sample through the dipstick matrix. Dilution series experimentsrevealed the sensitivity of detection to be 25 fmol (i.e. 400 μl of 62.5pM target) (see FIG. 3).

To determine the effect of strip surface area and feature diameter onthe speed and sensitivity of detection, lateral flow microarray stripswere introduced to 10 μl of sample solution containing 20 nM, 2 nM and 0mM target concentration (FIG. 4). Specific detection of the target wasobtained within 1 minute. The sensitivity was found to be 20 fmol oftarget (i.e. detection of 2 nM target in 10 μl sample volume). Thereduced surface area and sample volume result in more rapid detectionthan observed with dipsticks of more tradition size. Moreover, thesensitivity of the dipstick microarray was similar to that of the largerdipstick in terms of fmol detected. Thus, the DNA dipstick microarraysoffer a more rapid detection platform with similar detection thresholdsto those of larger strips while offering the increased informationcapacity inherent to high density microarray technology.

Example 4 Construction of Exemplary LFM Device Materials and Methods:

LFM Fabrication: Lateral flow microarrays (LFMs) were printed using aNanoPlotter 2.0 (GeSim, mbH, Dresden, Germany) non-contact picoliterdeposition system equipped with NanoTips (GeSim). Unless otherwiseindicated, LFMs were patterned with 400 μM solutions of oligonucleotidein H₂O containing a 1:50 dilution of Ponceau S (P7767, Sigma) as atracking dye. A lateral flow compatible nitrocellulose membrane (HiFlow135, Millipore) was used as the LFM substrate. Following oligonucleotidedeposition, nitrocellulose membranes were air dried and exposed to 5000μJ UV in a StrataLinker (Stratagene). The resulting membrane sheets werecut into 3 mm wide, 30 mm long strips which were either used directlywith buffer suspended dyed microspheres or assembled with conjugaterelease pads into a custom plastic housing. Housings were fabricatedfrom polycarbonate sheet cut using a CO₂ laser (VersaLaser VL-300,Universal Laser Systems, Inc., Scottsdale, Ariz., USA). Conjugaterelease pads were made by impregnating glass fibre conjugate pad(GFCP203000, Millipore) with dyed microspheres covalently conjugated toR-57-76-3TN (see below) in 1% SDS. Microsphere saturated release padswere allowed to air dry under ambient conditions prior to assembly withLFM membranes.

Capture and Detection Oligonucleotides: Table 1 provides capture anddetection oligonucleotide sequences, their binding sites within the plcRamplicon are depicted in FIG. 5B. Amine modification and a T₁₈ spacersequence were included on the 3′ end of detection oligonucleotideR-57-76-3TN to allow covalent cross-linking to dyed microspheres and tofacilitate hybridization in lateral flow sandwich assays respectively.

Conjugation of Detection Oligonucleotides to Dyed Microspheres: SPHERO™carboxyl-polystyrene 0.35 μm blue microspheres (Spherotech) werecovalently conjugated to amino modified oligonucleotide R-57-76-3TNusing the coupling agent 1-etyl-3-(3-dimethylaminopropyl-diimide HCl(EDAC, Pierce) under conditions adapted from Spiro et al (32). Briefly,4×10¹⁰ microspheres were suspended in 100 mM2-(N-morpholino)ethanesulfonic acid pH 4.5 (MES, Sigma). Indicatedamounts of oligonucleotide were introduced to MES suspendedmicrospheres, vortexed and incubated in the presence of 0.5 mg/ml EDAC.Reactions were protected from light in aluminum foil wrapped tubes andincubated at room temperature for 30 min followed by the introduction ofadditional EDAC to bring the final EDAC concentration to 1 mg/ml.Incubation was continued for an additional 30 min after which beads werewashed once with 1 ml 0.02% tween-20 (Sigma) and twice with 0.5 ml 0.1%SDS (Fisher Scientific). Beads were resuspended in 0.5 ml DNAase/RNAasefree H2O. Bead suspensions were assessed for aggregation byphase-contrast light microscopy using a Zeiss IM135 inverted microscope.

Results:

Oligonucleotides for hybridization sandwich assays were designed todetect NASBA amplified B. anthracis plcR mRNA or synthetic targets basedon relevant subregions of the plcR sequence. Oligonucleotidesimmobilized on the lateral flow substrate are referred to here ascapture oligonucleotides while those conjugated to dyed microspheres forsignal generation are referred to as detection oligonucleotides.Supported large pore nitrocellulose membranes were patterned withvarying concentrations of capture oligonucleotides using a NanoPlotter™2.0 robotic positioning system (GeSiM, Groβrkmannsdorf, Germany) andNanoTip piezoelectronically actuated micropipets (GeSiM).Oligonucleotide dnaR89 was printed on LFM substrates as a positivehybridization control as this oligonucleotide carries sequencecomplementary to bead coupled detection oligonucleotide R-57-76-3TN.Negative hybridization controls included {dot over (F)}-24-43 (thereverse complement of capture oligonucleotide R-24-43) and an unrelatedsequence complementary to a region of the F. tularensis sdhA locus(FT-S18) (Pardington et al., submitted). By ejecting droplets from themicropipet at a distance of 500 μm from the nitrocellulose substrate,microarray feature sizes of approximately 200 μm could be generated. Incontrast to contact microarray printing methods, this approach preservesthe fragile pore structure of the membrane required formicrosphere-based detection. Patterned nitrocellulose sheets were cutinto 3 mm wide strips and then assembled with conjugate release pads ina custom designed plastic housing. An example of the resulting device isshown in FIG. 6A. Hybridization-mediated capture of analyte at thecognate capture element of the microarray and non-overlappinghybridization to dyed microsphere conjugated detection oligonucleotidegenerates a colorimetric signal arising from an increased localconcentration of dyed microsphere particles. A schematic representationof the hybridization sandwich assay scheme is depicted in FIG. 6B.

Example 5 LFM Sandwich Hybridization Parameter Optimization Materialsand Methods:

LFM Fabrication: LFMs were fabricated as described in Example 4, infra.

Detection and Capture Oligonucleotides: Detection and captureoligonucleotides were designed as indicated in Example 4, infra.Conjugation of detection oligonucleotides to dyed, polystyrenemicrospheres was as described in Example 4.

Target Nucleic Acids: A DNA oligonucleotide, dnaR89, composed ofsequence derived from a region of the plcR gene of B. anthracis, asshown in FIG. 5B, was used to provide a readily available andquantifiable target for LFM assay development and optimization. Thesequence of this synthetic target is provided in Table 1. Additionally,a full-length synthetic target RNA was generated by PCR followed by invitro transcription. This RNA, referred to here as picRivt, was used toconfirm that reaction conditions established with dnaR89 were alsosuitable for the detection of NASBA reaction products. Synthesis ofplcRivt was accomplished by using pic-P1 and plc-P2 primers in PCRreactions containing 20 ng of B. anthracis Stern strain 7702 genomicDNA. PCR reactions using Platinum PCR Supermix (Invitrogen) wereconducted for 40 cycles of 94° C. for 30 s, 60° C. for 30 s and 72° C.for 1 min following an initial 2 min incubation at 94° C. The resultingamplicon was subjected to purification using QIAquick PCR clean-upspin-columns (QIAGEN) and subsequently used to program an in vitrotranscription reaction using the T7 AmpliScribe kit (EpiCentre). The invitro transcription reaction product was subjected to treatment withRNase free DNase I (Ambion) and purified using a RNeasy column (QIAGEN).The resulting RNA was quantified by measuring the OD₂₆₀. plcRivt ispredicted to be identical in sequence to the NASBA product generatedfrom B. anthracis total cellular RNA using plc-P1 and plc-P2.

Detection Protocol Following completion of sample flow, LFM membraneswere allowed to air dry prior to scanning with a standard flatbed PCscanner (CanoScan 9950F, Canon, Inc.). Scans were performed at 2400 dpiresolution using 48 bit color. The resulting image files were convertedto grayscale, inverted and saved as 16-bit TIFF files using PhotoshopCS2 (Adobe). Image files were then analyzed using GenePix Pro 6.0(Molecular Devices) to quantify microarray spot intensities for NASBAproduct detection and for dnaR89 dilution series experiments.

Results:

LFMs were fabricated using varying concentrations of captureoligonucleotide to determine optimum printing concentrations. Followinglateral flow of 25 fmol dnaR89 in 4×SSC, 5% formamide, 1.4% TritonX-100, 0.1% SDS containing 0.5% R-57-76-3TN coupled microspheres LFMswere scanned on a flatbed scanner and the resulting images quantified.For all capture sequences examined, 400 μM oligonucleotide printingconcentrations provided the most favorable signal intensity (FIG. 7A).Standard hybridization conditions employed for these and othercharacterization studies were determined through an iterative set ofoptimization experiments that examined the effects of ionic strength,formamide concentration and detection oligonucleotide to beadcross-linking ratios.

LFM Running Buffer Optimization:

Lateral flow running buffer was based on the widely used standard sodiumcitrate buffer (SSC) supplemented with 1.4% Triton X-100 and 0.1% SDS toreduce microsphere aggregation and 5% formamide to increasehybridization stringency and destabilize target secondary structure.Given the profound impact ionic strength has on the stringency of DNAhybridization (33,34), SSC concentration was varied from 1× to 9× andassay performance evaluated by densitometry of lateral flow microarraysfollowing hybridization sandwich assays conducted using 25 fmol of thesynthetic target dnaR89 or approximately 200 fmol of plcRivt. FIG. 7Bsummarizes the results of SSC concentration optimization experiments.Near optimal signal intensity was obtained for both dnaR89 and plcRivtat SSC concentrations between 2× and 7×. 4×SSC was selected for use instandard LFM running buffer as it provided sensitive hybridization-baseddetection of plcR derived sequences and good capillary lateral flowcharacteristics.

To determine the optimum concentration of formamide in LFM runningbuffer, a series of LFM experiments were conducted at varying formamideconcentrations using both dnaR89 and plcRivt. 10 μl of 4×SSC, 1.4%Triton X-100 and 0.1% SDS containing 25 fmol dnaR89 or approximately 200fmol plcRivt and varying concentrations of formamide, as indicated inFIG. 7C, were subjected to LFM analysis and the resulting hybridizationsignals quantified by densitometry. These experiments revealed a slightbut reproducible increase in signal intensity at 5% formamide. Allsubsequent studies presented here were performed using 4×SSC, 1.4%Triton X-100, 0.1% SDS, and 5% formamide.

Optimization of Oligonucleotide-Detection Microsphere Coupling:

Given that higher stock concentrations of synthetic oligonucleotidednaR89 could be obtained which allowed high confidence quantification ofthis synthetic target relative to what could be achieved withcomparatively dilute solutions of the in vitro transcription productplcRivt, subsequent LFM characterization studies made use of dnaR89. Thesimilarity of buffer optima displayed dnaR89 and plcRivt synthetictargets supported the assertion that dnaR89 could be used as an accurateproxy for the performance of LFM assays for NASBA product detection.Others have reported similar findings concluding that appropriatelydesigned DNA oligonucleotides can be used as synthetic targets for thedevelopment of assays ultimately used for NASBA product detection (35).Therefore, subsequent LFM assay optimization and characterization wasconducted using dnaR89.

To determine the optimum ratios for cross-linking detectionoligonucleotides to dyed polystyrene microspheres, we examinedpopulations of beads coupled to oligonucleotide at varying ratios. The3′ amine modified detection oligonucleotide R-57-76-3TN was covalentlylinked to polystyrene dyed microspheres using EDAC. The resultingbead/oligonucleotide complexes were evaluated for their ability tomediate detection of dnaR89 in a hybridization sandwich assay. Couplingreactions using a 2.2×10⁴:1 oligonucleotide to bead ratio were found toprovide optimum signal as determined by densitometry (FIG. 7D).

Example 6 Characterization of LFM Assay Detection Sensitivity Materialsand Methods:

LMF fabrication, oligonucleotide conjugation protocols, target nucleicacids and detection protocols were as described in Examples 4 and 5,supra.

Variable Detection Oligonucleotides: Detection oligonucleotideR-57-76-3TN carrying a 3′ spacer region consisting of 18 T residues wascompared to detection oligonucleotide R-57-76-3N, carrying the sameanalyte complementary sequence as R-57-76-3TN but without the T₁₈spacer, in order to evaluate whether the poly-T spacer influencesaccessibility of microsphere-coupled detection oligonucleotides to theirhybridization targets.

Variable Capture Oligonucleotides: To determine the relative performanceof hybridization sandwich assays making use of capture oligonucleotideswith complementarity to different locations of the target sequence,three capture oligonucleotides were synthesized and compared usingsandwich assays employing detection oligonucleotide R-57-76-3TN coupleddyed microspheres. R-77-96 was designed to participate in base stackingwith R-57-76-3TN when hybridized to the target. Base stacking has beenreported to stabilize hybridization and allow efficient capture ofdilute nucleic acids by hybridization (38-42). The binding sites for thethree capture oligonucleotides examined (R-77-96, R-36-55, and R-24-43)are illustrated in FIG. 5B. Varying quantities of synthetic targetdnaR89, between 0 and 200 fmol, were used for these studies.

Results:

Detection oligonucleotide spacer improves hybridization efficiency: Thedetection oligonucleotide R-57-76-3TN carried a 3′ spacer regionconsisting of 18 T residues to increase the accessibility of bead boundoligonucleotides for hybridization. R-57-76-3N, which carried the sameanalyte complementary sequence as R-57-76-3TN but without the T₁₈spacer, was found to exhibit significantly reduced hybridization todnaR89 consistent with prior reports that a poly(dT) spacer sequenceincreases hybridization efficiency to solid-phase coupledoligonucleotides (36,37). T₁₈ spacers were not incorporated into LFMimmobilized capture oligonucleotides as they were found to bedispensable for hybridization.

FIG. 8 depicts LFM membranes following detection of the indicatedamounts of target oligonucleotide dnaR89. Images were collected using aflatbed scanner at 2400 dpi optical resolution, 48-bit color. LFMscarried dnaR89, which hybridizes directly to the microsphere conjugateddetection probe, as a positive hybridization control. Positive controlfeatures were printed as the left most element of each LFM row to assistin feature identification. Negative hybridization controls, F24-43 andFT-S18, were based on the reverse complement of R-77-96 and an unrelatedF. tularensis derived sequence respectively. Additionally, to confirmthat no carryover contamination occurred during printing, H₂O containingPonceau S was printed on LFM substrates between positive control andcapture oligonucleotide deposition. No signal was detectable in eitherhybridization negative controls or H₂O negative control microarrayelements.

Base stacking effect: Background corrected signal intensity wasdetermined from LFM images using GenePix Pro 6.0 microarray dataextraction software. The results, presented in FIG. 9A, reveal R77-96produces significantly higher hybridization signals than R-36-55 orR-24-43 for all examined quantities of dnaR89, suggesting a significantcontribution of base stacking effects to LFM hybridization sandwichassay sensitivity.

LFM Detection Sensitivity: To define the detection limit of the LFMassay, a one-tailed t-test was used to determine quantities of dnaR89that generated signal intensities significantly above 0 amol negativecontrols. Signals generated at R-77-96 capture features with 250 amoland greater quantities of dnaR89 were significantly higher than 0 amoldnaR89 controls (p<0.05, n=6). By the same criterion, 1 fmol dnaR89detection limits were obtained for both R-24-43 and R-36-55 (p<0.05,n=6). FIG. 9B depicts the performance of LFM detection over the 0 to2500 amol dnaR89 range using the R-77-96/R-57-76-3TN capture/detectionprobes. LFM detection exhibited excellent linearity, R²=0.989, over this10 fold range of target molecules. While capture probe R-24-43 exhibitedless sensitivity than R-77-96, this capture probe displayed excellentsignal linearity between 2.5 fmol and 100 fmol dnaR⁸⁹, R²=0.968 (FIG.9C). These findings demonstrate that the LFM capacity to displaymultiple capture sequences can be used to simultaneously providesensitive detection and extend assay linearity through the use ofcapture probes with differing hybridization characteristics.

Example 7 LFM Assay Time Course Evaluation Materials and Methods:

LMF fabrication, oligonucleotide conjugation protocols, target nucleicacids and detection protocols were as described in Examples 4 and 5,supra.

For these time course studies, LFM assays were recorded using a digitalvideo recorder (DCR-PC1, Sony). Video frames were collected forquantification using iMovie (Apple Computer). Feature intensity wasquantified for time course studies and some optimization experimentsusing uncalibrated optical density in ImageJ(http://rsb.info.nih.gov/ij/). For better reproduction contrast, LFMimages used for figures were cropped and modified by applying the AutoContrast function in Photoshop CS2. No other modifications were applied.

Results:

The small sample volumes used for LFM detection and the reduced surfacearea traversed during capillary lateral flow significantly reducesdetection times for the LFM relative to traditional lateral flowdevices. To quantitatively present the speed of LFM-mediated nucleicacid detection, we used digital video to follow hybridization sandwichassay mediated detection of synthetic target molecule dnaR89. Thesestudies were conducted over a range of target concentrations using 10 μlof LFM running buffer containing suspended R-57-76-3TN conjugated dyedmicrospheres. Individual frames were isolated from video data sets andquantified for relative signal intensity over the course of capillarylateral flow across the LFM substrate. The resulting signal data wasplotted versus time in seconds as shown in FIG. 10. For timemeasurements, to was defined as the time when the sample front reachedthe first row of LFM features. Signal was detectable for 1000 fmoltarget in 2 seconds following sample transport across R-77-96 captureelements. 100 fmol dnaR89 was detectable within 4 seconds while 10 fmolwas clearly detectable by 30 seconds as defined by the earliest timepoint at which 90% of the pixels composing the R-77-96 microarrayfeatures were greater than one standard deviation above background.Lateral flow transport of the 10 μl sample was complete by 120 seconds.

Example 8 LFM Assay for Detection of Bacillus anthracis Materials andMethods:

LMF fabrication, oligonucleotide conjugation protocols, target nucleicacids and detection protocols were as described in Examples 4 and 5,supra. Table 1 provides capture and detection oligonucleotide sequences;binding sites within the plcR amplicon are depicted in FIG. 5B. Aminemodification and a T₁₈ spacer sequence were included on the 3′ end ofdetection oligonucleotide R-57-76-3TN to allow covalent cross-linking todyed microspheres and to facilitate hybridization in lateral flowsandwich assays respectively.

RNA Isolation:

Total RNA was isolated from B. anthracis strain Sterne 7702 and B.thuringiensis strain HD 621 (29) using a previously reported protocol(30). Purified RNA was quantified by measuring OD₂₆₀ and evaluated bygel electrophoresis. 3×10⁸ cells were used for RNA isolation typicallyyielding 50-75 μg of total RNA.

Amplification Primer Design

Nucleic acid sequence based amplification (NASBA, (20)) primers, plc-P1and plc-P2, were designed to amplify a fragment of the plcR locus fromB. anthracis. Primer sequences used for NASBA reactions are provided inTable 1, the T7 promoter sequence is italicized in plc-P1. Plc-P1hybridizes to the plcR transcript such that the 3′ end of the primerforms a base pair with the previously reported polymorphism strictlyassociated with B. anthracis (27,28). The NASBA P2 primer, pic-P2, islocated such that the amplified RNA resulting from NASBA is 179 bases inlength, see FIG. 5A. Previously reported plcR-based B. anthracisreal-time PCR assays (27,28) have made use of an alternate upstreamprimer that generates a 83 bp product but may be poorly suited for NASBAgiven the optimal NASBA product size of 120-250 bases (31).

Nucleic Acid Sequence-Based Amplification (NASBA)

NASBA reactions were prepared according to the manufacturer'sinstructions using the NucliSens Basic kit (Biomerieux) and primerspic-P1 and plc-P2 at 0.4 μM each. Amounts of total cellular bacterialRNA were varied, as indicated, between 0 and 2 ng. B. anthracis Sterne7702 was used as a test strain and B. thuringiensis strain HD 621 wasemployed as a negative control. 1 μg of human total cellular RNAisolated from HeLa S3 cells (Stratagene) was included in all NASBAreactions to provide a complex RNA background consistent with thecomposition of human diagnostic samples. Following a 60 minuteincubation at 41° C., NASBA reaction products were detected by using alateral flow microarray (LFM).

Detection of NASBA reaction products: Detection of NASBA products wasaccomplished by introducing a 2 μl aliquot of a 20 μl NASBA reactioninto 8 μl of LFM running buffer (final buffer composition: 4×SSC, 0.1%SDS, 1.4% Triton X-100, 5% deionized formamide, and 0.5% w/v R-57-76-3TNcoupled 0.35 μm dyed microspheres). The final volume of solution appliedto LFMs was 10 μl. Following completion of sample flow, LFM membraneswere allowed to air dry prior to scanning with a standard flatbed PCscanner (CanoScan 9950F, Canon, Inc.). Scans were performed at 2400 dpiresolution using 48 bit color. The resulting image files were convertedto grayscale, inverted and saved as 16-bit TIFF files using PhotoshopCS2 (Adobe). Image files were then analyzed using GenePix Pro 6.0(Molecular Devices) to quantify microarray spot intensities for NASBAproduct detection and for dnaR89 dilution series experiments.

Results:

Prior reports have described a single nucleotide polymorphism (SNP)present in B. anthracis but not close phylogenetic near neighborsincluding B. cereus and B. thuringiensis (27,28). This SNP has been usedas the basis for a sensitive and highly discriminatory real-time PCRassay for B. anthracis (28). To determine the utility of LFM technologyfor detecting minority nucleic acids in complex samples, NASBA primerswere designed to amplify the plcR allele of B. anthracis.

Varying amounts of total cellular RNA isolated from B. anthracis or 2 ngof B. thuringiensis HD 621 RNA as a negative control were introduced to1 μg of total human cellular RNA isolated from HeLa S3 cells. Theresulting mixtures were subjected to NASBA amplification using plc-P1and plc-P2 primers. Human RNA was included in NASBA amplificationreactions to approximate the nucleic acid complexity expected in humandiagnostic specimens. 2 μl of NASBA reaction mixture was removed after a60 minute incubation at 41° C., mixed with 8 μl of LFM running bufferand assayed for plcR amplicon by LFM. Dyed microspheres cross-linked toR-57-76-3TN were used for detection of NASBA amplicons captured on LFMscarrying R-77-96. Data from these studies are presented in FIG. 11.Following 60 minutes of NASBA amplification, as little as 0.5 pg fortotal cellular B. anthracis RNA could be detected in a background matrixof 1 μg of human total RNA. These studies closely approximate theconditions expected for complex human diagnostic samples and reveal thecapacity of the LFM platform to specifically detect NASBA reactionproducts generated from mixed samples where the target sequence is aminority species. While the number of plcR mRNA copies in a B. anthraciscell has not been determined, an estimate of LFM assay sensitivity, interms of B. anthracis cells, can be calculated based on total RNAyields. Total RNA yields from vegetative B. anthracis were in the rangeof approximately 167-250 fg RNA/cell. Using this value, an estimate ofLFM sensitivity corresponds to the detection of approximately to 2-3 B.anthracis cells.

Example 9 LFMs Utilizing Semi-Conductor Nanocrystal Detection ParticlesExhibit Exceptional Linear Dynamic Range

To assess the impact of a fluorescent reporter on the linear dynamicrange of LFM mediated analyte detection, a combined colorimetric andfluorescent detection scheme was devised. In this detection scheme,conjugated dyed microspheres as well as streptavidin conjugatedfluorescent semi-conductor nanocrystals (605 nm emission, Qdots,InVitrogen, Inc.) are used simultaneously as the reporter particles. Forthese experiments a detection oligonucleotide, R-57-76-3TBIO(5′-AGGTGAGACATAATCATGCATTTTTTTTTU-biotinTTTTU-biotinTTTTU-biotin3′)[SEQ ID NO: 13], carrying three biotin-modified nucleotides was employedin hybridization sandwich assays. Following lateral flow of 250 amol ofsynthetic analyte dnaR89 in 10 μl of standard LFM running buffer, LFMstrips were photographed under ambient light and under illumination witha hand-held UV-LED flashlight (FIG. 12);

As illustrated in FIG. 12, this detection scheme clearly allows thesimultaneous visualization of hybridization events using both dyedmicrosphere-mediated colorimetry and semi-conductor nanocrystal-mediatedfluorescent visualization even in the absence of optical filters. Whileexcitation and emission filters may further benefit the sensitivity andsignal-to-noise ratio exhibited, they are clearly not required forvisualization of nanocrystal-based LFM signals.

To quantify fluorescent nanocrystal LFM signal response linearity, LFMswere challenged with 1, 5, 10, 50, 100, 500, 1000 fmol of dnaR89.Following lateral flow of these samples, LFM strips were adhered to aglass microscope slide and scanned using a standard scanning lasermicroarray reader (GenePix 4200 Pro, Axon Instruments). A 488 nm laserwas used as the excitation source. The resulting data, shown in FIG. 13,illustrate remarkable signal linearity over the 1 fmol to 1000 fmolrange of dnaR89 (R²=0.991).

TABLE 1 Function Name Sequence Bead Conjugation/Detection R-57-76-3TN5′-AGGTGAGACATAATCATGCA TTTTTTTTTTTTTTTTTT-NH2-3′ Probe [SEQ ID NO: 14]Detection Probe/Negative R-57-76-3N 5′-AGGTGAGACATAATCATGCA-NH2-3′Control [SEQ ID NO: 15] LFM Immobilized Capture R-77-965′-TAATAAAGAGTTTGATGTGA-3′ Probe [SEQ ID NO: 16] LFM Immobilized CaptureR-36-55 5′-AAGCATTATACTTGGACAAT-3′ Probe [SEQ ID NO: 17] LFM ImmobilizedCapture R-24-43 5′-TGGACAATCAATACGAATAA-3′ Probe [SEQ ID NO: 18]Synthetic target/Positive dnaR895′CAAAGCGCTTATTCGTATTGATTGTCCAAGTATAATGCTTTTGCATG Hyb ControlATTATGTCTCACCTTCACATCAAACTCTTTATTATCATGTAA-3′ [SEQ ID NO: 19] NASBA/Invitro plcRivt 5′-GGGAGAUUUGCAUGACAAAGCGCUUAUUCGUAUUGAUUGUCCAAGUtranscription product AUAAUGCUUUUGCAUGAUUAUGUCUCACCUUCACAUCAAACUCUUUAUUAUCAUGUAAUACUUCUAAUUGCUUUAAUAUAUUUUCAUAUAACUCAAUACUCUUCUUAAAAUGGCCAUUUUCAGCGUAAAUGUU-3′ [SEQ ID NO: 20] Negative HybControl FT-S18 5′- GCGGTCCCAAAAGGGTCAGTCGTAGCACACCACTTTCA-3′ [SEQ ID NO:21] Negative Hyb Control F-24-43 5′-TTATTCGTATTGATTGTCCA-3′ SEQ ID NO:22] NASBA-P1/Allele plc-P15′-TTCTAATACGACTCACTATAGGGAGATTTGCATGACAAAGCGCTT Discrimination A-3′[SEQ ID NO: 23] NASBA-P2 plc-P2 5′-AACATTTACGCTGAAAATGGCCA-3′ [SEQ IDNO: 24]

CITED LITERATURE

-   1. Huckle, D. (2006) Point-of-care diagnostics: will the hurdles be    overcome this time? Expert Rev Med Devices, 3, 421-426.-   2. Yang, S, and Rothman, R. E. (2004) PCR-based diagnostics for    infectious diseases: uses, limitations, and future applications in    acute-care settings. Lancet Infect Dis, 4, 337-348.-   3. Chin, C. D., Linder, V. and Sia, S. K. (2007) Lab-on-a-chip    devices for global health: past studies and future opportunities.    Lab Chip, 7, 41-57.-   4. Koch, W. H. (2004) Technology platforms for pharmacogenomic    diagnostic assays. Nat Rev Drug Discov, 3, 749-761.-   5. Mackay, I. M. (2004) Real-time PCR in the microbiology    laboratory. Clin Microbiol Infect, 10, 190-212.-   6. Cirino, N. M., Musser, K. A. and Egan, C. (2004) Multiplex    diagnostic platforms for detection of biothreat agents. Expert Rev    Mol Diagn, 4, 841-857.-   7. Petrik, J. (2006) Diagnostic applications of microarrays.    Transfus Med, 16, 233-247.-   8. Heller, M. J. (2002) DNA microarray technology: devices, systems,    and applications. Annu Rev Biomed Eng, 4, 129-153.-   9. Peytavi, R., Raymond, F. R., Gagne, D., Picard, F. J., Jia, G.,    Zoval, J., Madou, M., Boissinot, K., Boissinot, M., Bissonnette, L.    et al. (2005) Microfluidic device for rapid (<15 min) automated    microarray hybridization. Clin Chem, 51, 1836-1844.-   10. Wei, C. W., Cheng, J. Y., Huang, C. T., Yen, M. H. and    Young, T. H. (2005) Using a microfluidic device for 1 microl DNA    microarray hybridization in 500 s. Nucleic Acids Res, 33, e78.-   11. Lim, D. V., Simpson, J. M., Kearns, E. A. and    Kramer, M. F. (2005) Current and developing technologies for    monitoring agents of bioterrorism and biowarfare. Clin Microbiol    Rev, 18, 583-607.-   12. Glynou, K., loannou, P. C., Christopoulos, T. K. and    Syriopoulou, V. (2003) Oligonucleotide-functionalized gold    nanoparticles as probes in a dry-reagent strip biosensor for DNA    analysis by hybridization. Anal Chem, 75, 4155-4160.-   13. Rule, G. S., Montagna, R. A. and Durst, R. A. (1996) Rapid    method for visual identification of specific DNA sequences based on    DNA-tagged liposomes. Clin Chem, 42, 1206-1209.-   14. Dineva, M. A., Candotti, D., Fletcher-Brown, F., Allain, J. P.    and Lee, H. (2005) Simultaneous visual detection of multiple viral    amplicons by dipstick assay. J Clin Microbiol, 43, 4015-4021.-   15. Kozwich, D., Johansen, K. A., Landau, K., Roehl, C. A.,    Woronoff, S. and Roehl, P. A. (2000) Development of a novel, rapid    integrated Cryptosporidium parvum detection assay. Appl Environ    Microbiol, 66, 2711-2717.-   16. Zuiderwijk, M., Tanke, H. J., Sam Niedbala, R. and    Corstjens, P. L. (2003) An amplification-free hybridization-based    DNA assay to detect Streptococcus pneumoniae utilizing the    up-converting phosphor technology. Clin Biochem, 36, 401-403.-   17. Zijlmans, H. J., Bonnet, J., Burton, J., Kardos, K., Vail, T.,    Niedbala, R. S, and Tanke, H. J. (1999) Detection of cell and tissue    surface antigens using up-converting phosphors: a new reporter    technology. Anal Biochem, 267, 30-36.-   18. Duck, P., Alvarado-Urbina, G., Burdick, B. and    Collier, B. (1990) Probe amplifier system based on chimeric cycling    oligonucleotides. Biotechniques, 9, 142-148.-   19. Piepenburg, O., Williams, C. H., Stemple, D. L. and    Armes, N. A. (2006) DNA detection using recombination proteins. PLoS    Biol, 4, e204.-   20. Compton, J. (1991) Nucleic acid sequence-based amplification.    Nature, 350, 91-92.-   21. Kievits, T., van Gemen, B., van Strijp, D., Schukkink, R.,    Dircks, M., Adriaanse, H., Malek, L., Sooknanan, R. and    Lens, P. (1991) NASBA isothermal enzymatic in vitro nucleic acid    amplification optimized for the diagnosis of HIV-1 infection. J    Virol Methods, 35, 273-286.-   22. Malek, L., Sooknanan, R. and Compton, J. (1994) Nucleic acid    sequence-based amplification (NASBA). Methods Mol Biol, 28, 253-260.-   23. Fong, W. K., Modrusan, Z., McNevin, J. P., Marostenmaki, J.,    Zin, B. and Bekkaoui, F. (2000) Rapid solid-phase immunoassay for    detection of methicillin-resistant Staphylococcus aureus using    cycling probe technology. J Clin Microbiol, 38, 2525-2529.-   24. Baeumner, A. J., Schlesinger, N. A., Slutzki, N. S., Romano, J.,    Lee, E. M. and Montagna, R. A. (2002) Biosensor for dengue virus    detection: sensitive, rapid, and serotype specific. Anal Chem, 74,    1442-1448.-   25. Baeumner, A. J., Pretz, J. and Fang, S. (2004) A universal    nucleic acid sequence biosensor with nanomolar detection limits.    Anal Chem, 76, 888-894.-   26. Hartley, H. A. and Baeumner, A. J. (2003) Biosensor for the    specific detection of a single viable B. anthracis spore. Anal    Bioanal Chem, 376, 319-327.-   27. Zaytseva, N. V., Montagna, R. A., Lee, E. M. and    Baeumner, A. J. (2004) Multi-analyte single-membrane biosensor for    the serotype-specific detection of Dengue virus. Anal Bioanal Chem,    380, 46-53.-   28. Edwards, K. A. and Baeumner, A. J. (2006) Optimization of    DNA-tagged dye-encapsulating liposomes for lateral-flow assays based    on sandwich hybridization. Anal Bioanal Chem, 386, 1335-1343.-   29. Easterday, W. R., Van Ert, M. N., Simonson, T. S., Wagner, D.    M., Kenefic, L. J., Allender, C. J. and Keim, P. (2005) Use of    single nucleotide polymorphisms in the plcR gene for specific    identification of Bacillus anthracis. J Clin Microbiol, 43,    1995-1997.-   30. Easterday, W. R., Van Ert, M. N., Zanecki, S, and    Keim, P. (2005) Specific detection of bacillus anthracis using a    TaqMan mismatch amplification mutation assay. Biotechniques, 38,    731-735.-   31. Hill, K. K., Ticknor, L. O., Okinaka, R. T., Asay, M., Blair,    H., Bliss, K. A., Laker, M., Pardington, P. E., Richardson, A. P.,    Tonks, M. et al. (2004) Fluorescent amplified fragment length    polymorphism analysis of Bacillus anthracis, Bacillus cereus, and    Bacillus thuringiensis isolates. Appl Environ Microbiol, 70,    1068-1080.-   32. Pannucci, J., Cai, H., Pardington, P. E., Williams, E.,    Okinaka, R. T., Kuske, C. R. and Cary, R. B. (2004) Virulence    signatures: microarray-based approaches to discovery and analysis.    Biosens Bioelectron, 20, 706-718.-   33. Deiman, B., van Aarle, P. and Sillekens, P. (2002)    Characteristics and applications of nucleic acid sequence-based    amplification (NASBA). Mol Biotechnol, 20, 163-179.-   34. Spiro, A., Lowe, M. and Brown, D. (2000) A bead-based method for    multiplexed identification and quantitation of DNA sequences using    flow cytometry. Appl Environ Microbiol, 66, 4258-4265.-   35. Albretsen, C., Haukanes, B. I., Aasland, R. and    Kleppe, K. (1988) Optimal conditions for hybridization with    oligonucleotides: a study with myc-oncogene DNA probes. Anal    Biochem, 170, 193-202.-   36. Schildkraut, C. (1965) Dependence of the melting temperature of    DNA on salt concentration. Biopolymers, 3, 195-208.-   37. Blake, R. D. and Delcourt, S. G. (1996) Thermodynamic effects of    formamide on DNA stability. Nucleic Acids Res, 24, 2095-2103.-   38. Baeumner, A. J., Leonard, B., McElwee, J. and    Montagna, R. A. (2004) A rapid biosensor for viable B. anthracis    spores. Anal Bioanal Chem, 380, 15-23.-   39. Guo, Z., Guilfoyle, R. A., Thiel, A. J., Wang, R. and    Smith, L. M. (1994) Direct fluorescence analysis of genetic    polymorphisms by hybridization with oligonucleotide arrays on glass    supports. Nucleic Acids Res, 22, 5456-5465.-   40. Day, P. J. R., Flora, P. S., Fox, J. E. and Walker, M. R. (1991)    Immobilization of polynucleotides on magnetic particles: Factors    Influencing hybridization efficiency. Biochem. J., 278, 735-740.-   41. O'Meara, D., Nilsson, P., Nygren, P. A., Uhlen, M. and    Lundeberg, J. (1998) Capture of single-stranded DNA assisted by    oligonucleotide modules. Anal Biochem, 255, 195-203.-   42. Lane, M. J., Paner, T., Kashin, I., Faldasz, B. D., Li, B.,    Gallo, F. J. and Benight, A. S. (1997) The thermodynamic advantage    of DNA oligonucleotide ‘stacking hybridization’ reactions:    energetics of a DNA nick. Nucleic Acids Res, 25, 611-617.-   43. O'Meara, D., Yun, Z., Sonnerborg, A. and Lundeberg, J. (1998)    Cooperative oligonucleotides mediating direct capture of hepatitis C    virus RNA from serum. J Clin Microbiol, 36, 2454-2459.-   44. Kandimalla, E. R., Manning, A., Lathan, C., Byrn, R. A. and    Agrawal, S. (1995) Design, biochemical, biophysical and biological    properties of cooperative antisense oligonucleotides. Nucleic Acids    Res, 23, 3578-3584.-   45. Kieleczawa, J., Dunn, J. J. and Studier, F. W. (1992) DNA    sequencing by primer walking with strings of contiguous hexamers.    Science, 258, 1787-1791.-   46. Cheek, B. J., Steel, A. B., Torres, M. P., Yu, Y. Y. and    Yang, H. (2001) Chemiluminescence detection for hybridization assays    on the flow-thru chip, a three-dimensional microchannel biochip.    Anal Chem, 73, 5777-5783.-   47. Roper, M. G., Easley, C. J. and Landers, J. P. (2005) Advances    in polymerase chain reaction on microfluidic chips. Anal Chem, 77,    3887-3893.-   48. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J.,    Higuchi, R., Horn, G. T., Mullis, K. B. and Erlich, H. A. (1988)    Primer-directed enzymatic amplification of DNA with a thermostable    DNA polymerase. Science, 239, 487-491.

All publications, patents, and patent applications cited in thisspecification are herein incorporated by reference as if each individualpublication or patent application were specifically and individuallyindicated to be incorporated by reference.

The present invention is not to be limited in scope by the embodimentsdisclosed herein, which are intended as single illustrations ofindividual aspects of the invention, and any which are functionallyequivalent are within the scope of the invention. Various modificationsto the models and methods of the invention, in addition to thosedescribed herein, will become apparent to those skilled in the art fromthe foregoing description and teachings, and are similarly intended tofall within the scope of the invention. Such modifications or otherembodiments can be practiced without departing from the true scope andspirit of the invention.

1. A lateral flow chromatographic device for detecting the presence ofat least one single-stranded target nucleic acid analyte in a fluidsample, comprising a chromatographic test strip which comprises (a) asample receiving zone for receiving an aliquot of the sample and forreceiving a labeled detection oligonucleotide, which detectionoligonucleotide comprises a sequence which is complementary to a firstsequence of the target nucleic acid; and, (b) a capture zone in lateralflow contact with the sample receiving zone, said capture zonecomprising a microporous membrane, onto which at least one captureoligonucleotide is immobilized at a feature size of 500 μm diameter orsmaller, and which comprises a sequence which is complementary to asecond sequence of the target nucleic acid.
 2. The lateral flowchromatographic device of claim 1, wherein the microporous membrane is 3mm or less in width.
 3. The lateral flow chromatographic device of claim1 wherein the sample receiving zone and the capture zone comprise acontiguous microporous membrane.
 4. The lateral flow chromatographicdevice of claim 1, wherein the microporous membrane is a lateral flowcompatible nitrocellulose membrane having a pore size of between 0.2 and20 μm.
 5. The lateral flow chromatographic device of claim 1, whereinthe detection oligonucleotide is labeled with a detectable particle ofbetween 0.02 and 1 μm in diameter.
 6. The lateral flow chromatographicdevice of claim 5, wherein the detectable particle is selected from thegroup consisting of polystyrene microspheres, latex particles, nano-goldparticles, colloidal gold particles, metal particles, magneticparticles, fluorescently detectable particles, and semi-conductornanocrystals.
 7. The lateral flow chromatographic device of claim 1,wherein the detection oligonucleotide comprises a first portion having asequence complementary to a part of the target sequence and a secondportion having a non-target specific sequence of at least 9 nucleotides,which second portion is adjacent to the label.
 8. The lateral flowchromatographic device of claim 7, wherein the second portion has a poly(A) or poly (T) sequence of at least 9 nucleotides.
 9. The lateral flowchromatographic device of claim 1, wherein the first sequence and secondsequence of the target nucleic acid are adjacent within 2 bases.
 10. Thelateral flow chromatographic device of claim 1, wherein the captureoligonucleotide is immobilized to the microporous membrane using anon-contact deposition method.
 11. The lateral flow chromatographicdevice of claim 1, wherein the detection oligonucleotide is replaced bya branched nucleic acid molecule or a dendrimeric nucleic acid molecule.12. The lateral flow chromatographic device of claim 1, wherein thecapture oligonucleotide has a feature size of between 50 and 300 μmdiameter.
 13. The lateral flow chromatographic device of claim 1,wherein the capture oligonucleotide has a feature size of between 50 and250 μm diameter.
 14. The lateral flow chromatographic device of claim 1,wherein the capture oligonucleotide has a feature size of between 50 and200 μm diameter.
 15. A lateral flow chromatographic device for detectingthe presence of at least one single-stranded target nucleic acid analytein a fluid sample, comprising a lateral flow matrix which defines a flowpath and which comprises in series: (a) a sample receiving zone forreceiving an aliquot of a fluid sample; (b) a labeling zone in lateralflow contact with said sample receiving zone, wherein the labeling zonecomprises a porous material containing at least one detectionoligonucleotide reversibly bound thereto, which detectionoligonucleotide is complementary to a first sequence of the targetnucleic acid and is coupled to a detectable label; and, (c) a capturezone in lateral flow contact with said labeling zone, said capture zonecomprising a microporous membrane, onto which at least one captureoligonucleotide is immobilized at a feature size of 500 μm diameter orsmaller.
 16. The lateral flow chromatographic device of claim 15,wherein the microporous membrane is 3 mm or less in width.
 17. Thelateral flow chromatographic device of claim 15 wherein the samplereceiving zone and the capture zone comprise a contiguous microporousmembrane.
 18. The lateral flow chromatographic device of claim 15,wherein the microporous membrane is a lateral flow compatiblenitrocellulose membrane having a pore size of between 0.2 and 20 μm. 19.The lateral flow chromatographic device of claim 15, wherein thedetection oligonucleotide is labeled with a detectable particle ofbetween 0.02 and 1 μm in diameter.
 20. The lateral flow chromatographicdevice of claim 19, wherein the detectable particle is selected from thegroup consisting of polystyrene microspheres, latex particles, nano-goldparticles, colloidal gold particles, metal particles, magneticparticles, fluorescently detectable particles, and semi-conductornanocrystals.
 21. The lateral flow chromatographic device of claim 15,wherein the detection oligonucleotide comprises a first portion having asequence complementary to a part of the target sequence and a secondportion having a non-target specific sequence of at least 9 nucleotides,which second portion is adjacent to the label.
 22. The lateral flowchromatographic device of claim 21, wherein the second portion has apoly (A) or poly (T) sequence of at least 9 nucleotides.
 23. The lateralflow chromatographic device of claim 15, wherein the first sequence andsecond sequence of the target nucleic acid are adjacent within 2 bases.24. The lateral flow chromatographic device of claim 15, wherein thecapture oligonucleotide is immobilized to the microporous membrane usinga non-contact deposition method.
 25. The lateral flow chromatographicdevice of claim 15, wherein the detection oligonucleotide is replaced bya branched nucleic acid molecule or a dendrimeric nucleic acid molecule.26. The lateral flow chromatographic device of claim 15, wherein thecapture oligonucleotide has a feature size of between 50 and 300 μm indiameter.
 27. The lateral flow chromatographic device of claim 15,wherein the capture oligonucleotide has a feature size of between 50 and250 μm in diameter.
 28. The lateral flow chromatographic device of claim15, wherein the capture oligonucleotide has a feature size of between 50and 200 μm in diameter.
 29. A method of testing for the presence of atarget nucleic acid in a liquid sample, comprising applying orcontacting the liquid sample to the sample receiving zone of the lateralflow chromatographic device according to claim 1, allowing the sample totransport by capillary action through the capture zone, and detectingthe presence or absence of the target nucleic acid by detecting thepresence of the label at the relevant capture zone feature.
 30. A methodfor detecting the presence of a target nucleic acid in a biologicalsample, comprising: (a) providing a biological sample suspected ofcontaining the target nucleic acid sequence; (b) releasing nucleic acidfrom the biological sample; (c) amplifying the target nucleic acid usingnucleic acid sequence based amplification (NASBA) to generate a solutioncontaining amplified single-stranded RNA complementary to the targetnucleic acid, if present in the extracted DNA and/or RNA from thebiological sample; and, (d) assaying for the presence of thecomplementary RNA target nucleic acid using the method according toclaim
 29. 31. A kit for testing the presence of a target nucleic acid ina sample, comprising: (a) a lateral flow chromatographic deviceaccording to claim 1; (b) a labeled detection oligonucleotidecomplementary to a second sequence in the target nucleic acid.
 32. Amethod of testing for the presence of a target nucleic acid in a liquidsample, comprising applying or contacting the liquid sample to thesample receiving zone of the lateral flow chromatographic deviceaccording to claim 15, allowing the sample to transport by capillaryaction through the capture zone, and detecting the presence or absenceof the target nucleic acid by detecting the presence of the label at therelevant capture zone feature.
 33. A method for detecting the presenceof a target nucleic acid in a biological sample, comprising: (a)providing a biological sample suspected of containing the target nucleicacid sequence; (b) releasing nucleic acid from the biological sample;(c) amplifying the target nucleic acid using nucleic acid sequence basedamplification (NASBA) to generate a solution containing amplifiedsingle-stranded RNA complementary to the target nucleic acid, if presentin the extracted DNA and/or RNA from the biological sample; and, (d)assaying for the presence of the complementary RNA target nucleic acidusing the method according to claim
 32. 34. A kit for testing thepresence of a target nucleic acid in a sample, comprising: (a) a lateralflow chromatographic device according to claim 15; (b) a labeleddetection oligonucleotide complementary to a second sequence in thetarget nucleic acid.
 35. A lateral flow microarray chromatographicdevice for detecting the presence or absence of a plurality ofsingle-stranded target nucleic acids in one or more fluid samples,comprising a lateral flow matrix which defines a flow path and whichcomprises in series: (a) a sample receiving zone for receiving the fluidsample(s); (b) a labeling zone in lateral flow contact with said samplereceiving zone, wherein the labeling zone comprises a porous materialcontaining a plurality of different detection oligonucleotidesreversibly bound thereto, which detection oligonucleotides arecomplementary to first sequences of a plurality of respective targetnucleic acids and are coupled to detectable labels; and, (c) a capturezone in lateral flow contact with said labeling zone, said capture zonecomprising a microporous membrane, at least a portion of which containsa plurality of different capture oligonucleotides immobilized thereto,which capture oligonucleotides are complementary to second sequences ofa plurality of respective target nucleic acids, and wherein thedifferent capture oligonucleotides are immobilized to the microporousmembrane at a feature size of 300 μm or less in diameter.
 36. Thelateral flow microarray of claim 35, wherein the different detectionoligonucleotides are coupled to differentiable detectable labels. 37.The lateral flow microarray of claim 35, wherein the differentiabledetectable labels are dyed polystyrene microspheres.
 38. The lateralflow microarray of claim 35, wherein the differentiable detectablelabels are semiconductor nanocrystals with different spectral emissioncharacteristics.
 39. A lateral flow microarray chromatographic devicefor detecting the presence or absence of a plurality of target nucleicacids in one or more fluid samples, comprising a lateral flow matrixwhich defines a flow path and which comprises in series: (a) a samplereceiving zone for receiving the fluid sample(s) and for receiving aplurality of different detection oligonucleotides, each of whichdetection oligonucleotides comprises a sequence which is complementaryto a first sequence of a specific target nucleic acid and is labeled;and, (b) a capture zone in lateral flow contact with said labeling zone,said capture zone comprising a microporous membrane, at least a portionof which contains a plurality of different capture oligonucleotidesimmobilized thereto, each of which capture oligonucleotides comprises asequence which is complementary to second sequence of the specifictarget nucleic acid, and wherein the different capture oligonucleotidesare immobilized to the microporous membrane at a feature size of 300 μmor less in diameter.
 40. The lateral flow microarray of claim 39,wherein the different detection oligonucleotides are coupled todifferentiable detectable labels.
 41. The lateral flow microarray ofclaim 39, wherein the differentiable detectable labels are dyedpolystyrene microspheres.
 42. The lateral flow microarray of claim 41,wherein the differentiable detectable labels are semiconductornanocrystals with different spectral emission characteristics.